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Abstract 
Medicinal mushrooms are known for their traditional use for the treatment of various diseases 
including diabetes, cancer and cardiovascular diseases. Mushrooms have been traditionally 
used for curing numerous life-threatening diseases such as cancer, Tuberculosis, Parkinson’s 
and Alzheimer. Cancer is one of the leading causes of death worldwide and finding better 
therapeutics to treat this disease is an urgent need. Literature demonstrates the potential of 
mushroom polysaccharides for their therapeutic value with significant immunostimulatory and 
anticancer activities with least side effects. A few polysaccharides from medicinal mushrooms 
(e.g. Polysaccharide Krestin, Polysaccharopeptide) are already in clinical use to treat cancer. 
This research therefore aims to isolate polysaccharides with immunomodulatory, prebiotic and 
anticancer properties from traditionally known medicinal mushrooms Ganoderma lucidum, 
Cordyceps sinensis and Trametes versicolor. The objectives of this research are to study the 
biological activities relevant to anticancer therapy and to evaluate the structure- function 
relationship of mushroom polysaccharides. It is therefore expected that these mushrooms have 
tremendous potential for the discovery of polysaccharides with immune enhancing, prebiotic 
and anti-cancer properties and hence chosen for this study. 
A total of six polysaccharides have been identified in this thesis from two medicinal mushrooms 
(G. lucidum and C. sinensis). Four of these fractions (GLP-1, GLP-2, GLP-3, CSP-1) have 
displayed significant radical scavenging activities. These activities correlated well with 
molecular masses and structural elements. GLP-1 and GLP-3 displayed highly significant 
immunostimulatory activities with respect to both cytokines and are extremely important 
candidate for immunotherapeutic applications. CSPs and GLPs have also displayed significant 




Overall, the results presented in this thesis strongly suggest immune enhancing, prebiotic and 
direct anticancer activities of polysaccharides from G. lucidum and C. sinensis (GLPs and 
CSPs). It is therefore concluded that these polysaccharides form potential candidates for 
combination “immuno-chemotherapy”. It is therefore suggested that, pre-treatment of cancer 
patients with immunostimulatory and prebiotic mushroom polysaccharides identified in this 
research to activate cancer microenvironment and to improve gut microbiota, followed by 
therapy with suitable immune checkpoint inhibitors is expected to produce enhanced outcomes 
for cancer patients. It is in this context that the immune enhancing and prebiotic mushroom 
polysaccharides discovered in this research have great potential in the treatment of cancer. 
 











Medicinal mushrooms are known for their traditional use for the treatment of various 
diseases including diabetes, cancer, and cardiovascular diseases (A.S and Ezeronye, 
2003, Cui and Chisti, 2003, Hattori et al., 2004). The edible and medicinal mushrooms 
are generally a source of health promoting compounds such as polysaccharides, dietary 
fibre, proteins and significant quantity of vitamins, and other phytochemicals 
(Kozarski et al., 2012, Nie et al., 2013). Presence of these compounds in mushrooms is 
responsible for their significant biological properties such as antioxidant, 
immunomodulatory, anti-tumour, anti-diabetic, antimicrobial, prebiotic, 
cardiovascular, and anti-inflammatory activities with low toxicities (Meng et al., 
2016). Mushroom polysaccharides have been reported to possess excellent antioxidant, 
immunostimulatory and anticancer activities (A.S and Ezeronye, 2003, Chen et al., 
2013, Cui and Chisti, 2003, Hattori et al., 2004, Ina et al., 2013). 
A few of the most widely studied traditional medicinal mushrooms are Coriolus 
versicolor, Schizophyllam commune, Lentinula edodes, Trametes versicolor, 
Ganoderma applanatum, Taxillus chinensis, Uncaria rhyncophylla, and Sanguisorba 
officinalis. These mushrooms contain polysaccharides with significant activities and 
their clinical use as antioxidant, immunomodulatory and antitumor agents is well 
established (A.S and Ezeronye, 2003, Hattori et al., 2004). 
As discussed before, traditional medicinal mushrooms have significant therapeutic 
potential for enhancing the immune system and for the treatment of cancer. Several 
species of traditional medicinal herbs/mushrooms suitable for the treatment of cancer 
have been described and documented in the literature (Huang and Zhang, 2005, Zhu et 
al., 2004). Mushrooms chosen in this study (G. lucidum and C. sinensis) are well 
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documented in the important traditional literature and currently employed by 
contemporary traditional practitioners for the treatment of various diseases including 
cancer. It is therefore expected that these mushrooms have tremendous potential for 
the discovery of polysaccharides with immune enhancing, prebiotic and anti-cancer 
properties and hence chosen for this study. 
In order to discover novel polysaccharide-based therapeutics from traditionally used 
mushrooms/herbs, it is necessary to: 
 Isolate and evaluate the biological and structural characteristics of 
polysaccharides from the chosen mushrooms 
 Undertake detailed investigations to identify the chemical structures and 
possible mechanism of action of purified herbal polysaccharides. 
These investigations have been successfully undertaken in this thesis with an aim to 
discover immune enhancing, prebiotic and anticancer polysaccharides and these 
interesting results are presented in Chapters 4 and 5. Previous research on these 
selected mushrooms is reviewed in Chapter 2. 
1.2 Thesis plan 
In order to address the above mentioned aims and objectives, this thesis is divided into 
six chapters that are described below. 
Chapter 1 provides an introduction to immuno-stimulatory and anticancer medicinal 
mushrooms and significance of their polysaccharides. The importance of employing 
contemporary scientific methods to develop effective immune enhancing, prebiotic and 
anticancer formulations with the active polysaccharides is also presented. This Chapter 
also provides the detailed plan of this thesis. 
Chapter 2 presents a detailed review of literature on medicinal mushrooms and their
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polysaccharides. A review of literature on oxidative stress and its link with the 
formation of cancer is also presented in Chapter 2. This chapter also presents a review 
of principles involved in various research methods employed in this thesis and relative 
merits of available options have been discussed. 
Chapter 3 presents the details of methodology employed for this research. Extraction 
and purification of polysaccharides, determination of biological activities (radical 
scavenging, immunomodulatory, prebiotic, and anticancer activities) and 
characterisation methods are described. Essentially, Chapter 3 provides one stop shop 
for all the methods employed in this research. 
Chapter 4 presents the results on purification, chemical characterisation, radical 
scavenging and immunomodulatory activities of polysaccharides from selected 
medicinal mushrooms. 
Chapter 5 presents the results on anticancer and prebiotic activities of polysaccharides 
from selected medicinal mushrooms. This chapter also presents FT-IR based structural 
characterisation of active mushroom polysaccharides. 
Chapter 6 The overall conclusions of this research and the suggestions for future 
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Mushrooms have a great history for their use as traditional as well as modern cuisine. 
Medicinal mushrooms are well-known for their traditional use for the treatment of 
various diseases including diabetes and cancer in Asian countries (A.S and Ezeronye, 
2003, Cui and Chisti, 2003b, Hattori et al., 2004). The edible and medicinal mushrooms 
are generally a source of health-promoting compounds such as polysaccharides, dietary 
fibre, proteins and a significant quantity of vitamins, minerals, and good cholesterol 
(Kozarski et al., 2012, Nie et al., 2013a). Presence of these compounds in mushrooms 
is responsible for their significant biological properties such as antioxidant, 
immunomodulatory and anti-tumour, anti-diabetic, antimicrobial, prebiotic, 
cardiovascular, and anti-inflammatory activities with low toxicities (Meng et al., 
2016). Mushroom polysaccharides have been reported to possess excellent antioxidant, 
immunostimulatory and anticancer activities (A.S and Ezeronye, 2003, Chen et al., 
2013, Cui and Chisti, 2003b, Hattori et al., 2004, Ina et al., 2013). Owing to these facts, 
extensive research has been carried out in the literature to investigate the spectrum of 
biological activities displayed by mushroom polysaccharides and to evaluate their 
structure-activity relationship (A.S and Ezeronye, 2003, Chen et al., 2013, Cui and 
Chisti, 2003b, Hattori et al., 2004, Ina et al., 2013). Many more mushrooms are being 
investigated in the literature with an aim to isolate polysaccharides with therapeutic 
value. Major emphasis is on the discovery of polysaccharides for immunotherapy and 
chemo-immunotherapy (Cui and Chisti, 2003a, Daba and Ezeronye, 2003, Kozarski et 
al., 2012, Zhang et al., 2018a, Zhang et al., 2013a, Zhang et al., 2012, Zhang and Reddy, 
2018, Zhang et al., 2018b). During the past couple of decades, several mushroom 
polysaccharides and other constituents were investigated for their biological activities 
with excellent results (Cui and Chisti, 2003b, Kozarski et al., 2012). There are around
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20,000 species of mushrooms in the nature and only a few hundred out of these show 
medicinal properties that are used as medicine and also as adjuvants to the conventional 
treatments (Alam et al., 2013, Chen et al., 2013, Patel and Goyal, 2012, Singdevsachan 
et al., 2016, Zhang et al., 2007). A few of the most widely studied traditional medicinal 
mushrooms are Coriolus versicolor, Schizophyllam commune, Lentinula edodes, 
Trametes versicolor, Ganoderma applanatum, Taxillus chinensis, Uncaria 
rhyncophylla, and Sanguisorba officinalis. These mushrooms contain polysaccharides 
with significant activities and their clinical use as an antioxidant, immunomodulatory 
and antitumor agents is well established (A.S and Ezeronye, 2003, Hattori et al., 2004). 
Mushroom polysaccharides display one or several biological activities depending on 
their structure. These details for some of the well-studied mushroom polysaccharides 
will be discussed later in this section. It has been demonstrated in the literature that 
anticancer polysaccharides possess immunomodulatory as well as antioxidant 
activities (Kozarski et al., 2012, Nie et al., 2013a, A.S and Ezeronye, 2003, Cui and 
Chisti, 2003b, Dunn et al., 2004, Ina et al., 2013, Zhang et al., 2012, Zhang et al., 
2013b). It is therefore important to determine the potent antioxidant and 
immunostimulatory polysaccharides as a first step towards the discovery of anticancer 
agents and to develop immune-chemotherapeutic strategies to treat cancer. 
It should be noted here that the process of the cancer formation is linked to Oxidative 
stress, inflammation and weakening of the immune system. The following sections 
highlight the relevance of Oxidative stress in the initiation of inflammation and other 
disease-causing conditions. Also, these sections discuss cancer immunosurveillance 
and the strategies by which cancer cells evade the immune response. A clear 
understanding of these topics (sections 2.2 to 2.6) is important for developing 
therapeutics/ adjuvants to treat cancer. 
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2.2 Oxidative stress, inflammation and cancer formation 
 
During metabolic processes, reactive oxygen species (ROS) are produced in the body. 
Some of the ROS include superoxide anion (O2
•ˉ), Hydroxyl radical (OH•), hydrogen 
peroxide (H2O2) (Alam et al., 2013, Jia et al., 2009, Kang et al., 2019, Umamaheswari 
and Chatterjee, 2007). Continuous environmental stress such as exposure to pollution 
and UV radiation also leads to the formation of free radicals in humans. The 
antioxidants present in the body (consumed in the form of food) continuously work to 
remove these toxic by-products (ROS). Any imbalance between the antioxidants and 
the amount of ROS produced in the body can lead to oxidative stress. Prolonged 
oxidative stress, in turn, leads to a serious imbalance between the production of 
reactive oxygen species and antioxidant defense. This prolonged imbalance can 
potentially lead to the destruction of biomolecules and eventually affect cells and the 
whole organism (Betteridge, 2000, Jomova and Valko, 2011, Lushchak, 2014). 
Unceasing oxidative stress causes further production of free radicals and inflammation 
in the body (Zhang et al., 2012). Inflammation occurs in two stages: acute 
inflammation and chronic inflammation. Acute inflammation lasts for a small duration 
in the body and can be readily eliminated by innate immunity (de la Fuente del Moral 
et al., 2005). In a situation when the innate immunity is weak and not sufficient 
antioxidants are consumed, inflammation can last longer leading to a chronic 
condition. Such chronic inflammation can result in the accumulation of free radicals 
and damage healthy cells (Topalian et al., 2011). Prolonged Oxidative stress and 
chronic inflammation leads to DNA mutation/damage and protein modification that 
could ultimately lead to carcinogenesis and results in cancer growth (Lushchak, 2014, 
Syn et al., 2017). Following flow chart illustrates the production of free radicals and 
their successive effects that lead to pro-carcinogenesis response (Betteridge, 2000, 
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la Fuente et al., 2005, Lushchak, 2014, Syn et al., 2017). 
 
 




2.3 Immune system before and after cancer formation 
 
Studies on animals and humans demonstrate that the immune system can recognise 
and eliminate cancer cells (Topalian et al., 2011). The immune system constitutes 
adaptive immunity and innate immunity. It is mentioned in cancer immune interaction 
studies that both innate and adaptive immunity involve the recognition and elimination 
of cancer cells (J. Frederick and L. Clayman, 2001). When the normal cells are changed 
into cancer cells, they are recognised and destroyed by T and NK cells. During this 
destruction macrophages and dendritic cells get activated to release inflammatory 
cytokines and produce multiply T-cells. Activation of T-cells generates more 
cytokines that further boost innate immunity (Dunn et al., 2004) which is partly 
responsible for the destruction of cancer cells and major action against cancer comes 
from the activated T cells. 
The immune system responds uniquely towards the elimination of various types of 
cancers. The outcomes of such an immune response are elimination, equilibrium and 
escape (Banerjee et al., 2018, Mittal et al., 2014). However, a few cancer cells are less 
immunogenic and do not activate the immune system. This results in proliferation of 
cancer cells (Dunn et al., 2004). Continuation of the sustained cycle weakens the 
immune system resulting in the escape stage and growth of cancer occurs (Lushchak, 
2014, Syn et al., 2017) which further leads to immune attenuation. More recently, it 
has been recognised that the T cell activation in the cancer microenvironment causes 
expression of additional proteins (CTLA-4 and PD-1) on T cell surface that are 
responsible escaping of cancer cells from immune response (Nishimura et al., 1998, 
Okazaki and Honjo, 2006, Sharma and Allison, 2015, Walunas et al., 1994). These are 
the important new developments and a detailed discussion of this topic is provided in 
section 2.4 below. 
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2.4 Evasion of cancer cells from T cell surveillance 
 
To understand the process of escaping of cancer cells from immune surveillance, a 
brief discussion on cytotoxic T cells and their function is provided below. 
Cytotoxic T cells (also known as cytotoxic T lymphocytes CTL or CD8+ T cells) 
serves to eliminate virally “infected cells” or “altered-self” cells including tumor cells 
(Mason, 2014). Such binding of the cytotoxic T cells through its own TCR and its CD8 
proteins to the infected cells lead to the process of cell differentiation and produces 
many activated cytotoxic T cells and memory cells that are specific for the unwanted 
target cells. These T cells can travel in the body and destroy unwanted (infected and 
tumor) cells (Mason, 2014). In fact, an intact healthy immune system has the ability to 
prevent the development and progression of cancer cells (Töpfer et al., 2011). Despite 
the presence of such an immune surveillance mechanism, the tumor cells develop 
variants that evade from the immune system and grows (Töpfer et al., 2011). There are 
several evasion strategies that cancer cells adapt to evade immune recognition and 
survive. These strategies include: 
 Owing to the mechanism of central tolerance, T cell activation is hampered by 
insufficient co-stimulation by CD28. 
 Large tumour burden in cancer patients can also trigger immunosuppression 
that can facilitate tumour progression. 
 Inhibitory co-receptors like programmed cell death-1 (PD-1) and cytotoxic T 
lymphocyte antigen-4 (CTLA-4) are overexpressed on T cells during T cell 
activation and these co-receptors bind with B7 family of proteins those are 
present in many tumour tissues (Töpfer et al., 2011). These co-receptor (CTLA-
4 and PD-1) compete with costimulatory T cell receptor CD28 in binding with 
the B7 family of molecules. This competing process is responsible for putting 
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the brakes on T cell activation resulting immune checkpoint (Chen et al., 2016,     
Curran et al., 2010a, Egen et al., 2002, Korman et al., 2006, Sharma and Allison, 2015, 
Wei et al., 2018, Wei et al., 2017). 
2.5 Cancer immunotherapy methods 
 
Until very recently, cancer treatment was a three-legged platform based on surgery, 
radiotherapy and chemotherapy (DeVita and Rosenberg, 2012). During the past couple 
of decades, immunotherapy, the fourth leg has been added and the cancer treatment 
now sits firmly on the four-legged platforms (DeVita and Rosenberg, 2012). Several 
immunotherapeutic modalities have been introduced during the past two decades that 
have significantly improved the outcomes of cancer treatment. A brief review of these 
methodologies is provided below. 
Development of methods to produce large quantities of antibodies having specificity 
has led to the success of antibody therapy to treat cancer (Kohler and Milstein, 1975). 
Rituximab and other antibodies were accepted for the treatment of B cell lymphoma 
(Maloney et al., 1997). These antibodies mainly function by the inhibition of growth 
factor receptors on cancer surface. Interleukin-2, a cytokine with immunomodulating 
effect, has been successfully used to treat metastatic melanoma and renal carcinoma 
(Rosenberg et al., 1985). This study represents the first successful immunotherapy to 
treat metastatic disease and achieved durable results (Rosenberg et al., 1985). 
Interleukin-2 was subsequently approved to treat the above mentioned two cancers. 
Multiple peptide-based vaccinations have been demonstrated to produce an immune 
response that was favourable to cure neck cancer (Yoshitake et al., 2015) and advanced 
oesophageal squamous cell carcinoma (Kono etal.,2012).
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Recognising the fact that immune checkpoint proteins (CTLA-4 and PD-1) described 
in section 2.4, provide major pathways for the cancer cells to evade T cell surveillance. 
Checkpoint inhibition therapy developed independently by Allison and co-workers & 
Honjo and co-workers (Nishimura et al., 1998, Okazaki and Honjo, 2006, Sharma and 
Allison, 2015, Walunas et al., 1994) inhibits such evasion pathways and T cells gain 
sufficient activation at attack and destroy cancer tumor cells. This therapy forms an 
important turning point in the treatment of cancer. A detailed description of “cancer 
immune checkpoint” and “cancer therapy using checkpoint inhibitors” is therefore 
included in section 2.6 below. 
2.6 Immune checkpoint inhibitors and cancer therapy 
 
Recent landmark discoveries of “cancer immune checkpoint” and “checkpoint 
inhibitors” mark a turning point in cancer immunotherapy (Chen et al., 2016, Curran et 
al., 2010a, Ishida et al., 2002, Korman et al., 2006, Nishimura et al., 1998, Nishimura and 
Honjo, 2001, Wei et al., 2017). Nobel laureates professor James Alison and professor 
Tasuku Honjo have unraveled the secrets of evasion of cancer cells from T cell 
surveillance (Minato and Honjo, 2016, Sharma and Allison, 2015). These novel 
“checkpoint inhibitors” mark a new approach to treat several types of tumor, that 
activates the immune system to kill tumor (Okazaki and Honjo, 2006, Wei et al., 2017). 
The important part of their discovery was to identify two different proteins (CTLA-4 
& PD-1) that are overexpressed on triggered T cells and these proteins put brakes on 
T cells hampering their ability to kill cancer. These proteins enable immune checkpoint 
on T cells and consequently cancer evades the immune system and grows (Weber, 
2010, Wei et al., 2017, Yoshitake et al., 2015). Inhibitors for CTLA-4 discovered by 
Professor Alison (Curran et al., 2010a, Daver et al., 2017) and inhibitors for PD-1 by 
professor Honjo (Chowdhury et al., 2018, Minato and Honjo, 2016, Nishimura et al.,
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1998, Nishimura and Honjo, 2001, Okazaki and Honjo, 2006) release the break caused 
by these immune checkpoint proteins. Consequently, T cells gain the ability to attack 
cancer cells. These novel “checkpoint inhibitors” mark a new approach to activate the 
immune system to kill tumor cells and has been successful to treat several types of 
tumors (Chowdhury et al., 2018, Curran et al., 2010a, Daver et al., 2017, Minato and 
Honjo, 2016, Nishimura et al., 1998, Nishimura and Honjo, 2001, Okazaki and Honjo, 
2006). This new approach is known as “immune checkpoint therapy”. 
2.6.1 Mechanism of action of immune checkpoint therapeutic agents 
 
The main objective of immune checkpoint therapy is to aim the pathways of T cells to 
intensify immune response towards tumour (Sharma and Allison, 2015). The 
antibodies used in the therapy do not kill the cancer cells directly, but they target the 
proteins (CTLA-4 & PD-1) involved in immune cell regulation (T cell regulation). 
Immune checkpoint therapy essentially activates the immune system to fight cancer 
(Sharma and Allison, 2015). Mechanism of action of immune checkpoint therapy is 
highlighted below. 
It is well recognised that the activation of T cell to fight cancer requires co-stimulation 
of CD28, a protein on the surface of T cell (Curran et al., 2010a, Daver et al., 2017, 
Sharma and Allison, 2015). Such a co-stimulation is established by binding of CD28 
with B & group of molecules that are expressed on either cancer cells or on the APC 
(Sharma and Allison, 2015). The T cells are then effectively activated and traffic the 
tumor site and attack cancer cells. However, T cell activation also initiates inhibitory 
pathways. In other words, the activated T cells express competing for molecules 
CTLA-4 which exhibits homologous structure to CD28. CTLA-4 binds with B7 group 
of molecules with a stronger binding affinity than CD28. This creates an inhibitory 
pathway that hinders CD28 co-stimulation and hence down-regulates the antitumor T
14  
cell responses (Krummel and Allison, 1995, Walunas et al., 1994). This mechanism is 
illustrated in Figure 2.2 below. 
 
 
Fig 2.2: Functioning of Check point inhibitors 
 
James P. Alison and co-workers (Ishida et al., 2002, Kono et al., 2012, Korman et al., 
2006, Krummel and Allison, 1996, Sharma and Allison, 2015) have proposed that 
inhibiting the interaction of CTLA-4 with B7 molecules might allow persistent CD28 
co-stimulation and hence prolongs the T cells activation results in an active antitumor 
immune response to eradicate the tumor. Ipilimumab is one of the antibodies that 
effectively bind with human CTLA04 that provides durable responses and larger 
survival rates (Schadendorf et al., 2015). Another protein that is capable of creating 
antitumor immune checkpoint is PD-1 that functions with a different mechanism 
(Greenwald et al., 2005, Ishida et al., 2002, Minato and Honjo, 2016, Nishimura et al., 
1998, Nishimura and Honjo, 2001, Okazaki and Honjo, 2006, Okazaki et al., 2002). 
The fact that CTLA-4 and PD-1 inhibitory pathways are different and their mechanisms 
of actions are non-overlapping, suggests that a combination therapy designed to inhibit 
both of these proteins (CTLA-4 & PD-1) is expected to be more effective than 
inhibiting one of them. Such a treatment indeed yielded better results (Curran et al., 
2010b, Wolchok et al., 2013). Immune checkpoint therapy has been extremely 
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successful but in a portion of cancer patients (Sharma and Allison, 2015). In cases 
where the treatment was successful, the patients have not shown any clinical signs of 
the disease for several years. In order to improve the applicability of this novel therapy 
to a large cross-section of patient base, a better understanding of T cell behaviour and 
immune response within the tumour microenvironment is required (Sharma and 
Allison, 2015). Additional inhibitory pathways may exist within the cancer 
microenvironment which may need to be targeted to make this novel therapy applicable 
to large numbers of cancer patients (Sharma and Allison, 2015). 
Extremely important studies are underway that are designed to determine the 
predictive markers with which to identify the cancer patients for immune checkpoint 
therapy with a specific antibody or combination (Sharma and Allison, 2015). 
substantial progress is required in this direction in order to improve the outcomes of 
immune checkpoint therapy for the majority of cancer patients. It is important to 
mention in this context that the ongoing program of research in our laboratory on 
polysaccharides from medicinal mushrooms and herbs is extremely relevant (Zhang et 
al., 2018a, Zhang et al., 2013a, Zhang and Reddy, 2018, Zhang et al., 2018b, Zhang et 
al., 2014). Abundant literature demonstrates that the herbal polysaccharides exhibit 
immunomodulatory activity and are proven to be suitable candidates for immuno- 
chemotherapy to enhance the survival rates of cancer patients (Cao and Lin, 2004, Cui 
and Chisti, 2003a, Hattori et al., 2004, Torisu et al., 1990, Umamaheswari and 
Chatterjee, 2007, Vetvicka and Vetvickova, 2012). It will also be interesting to 
investigate the inhibitory activity of mushroom polysaccharides towards immune 
checkpoint proteins like CTLA-4 & PD-1. Owing to the fact that these polysaccharides 
are non-toxic and exhibit anticancer/immunomodulatory properties, a carefully 
designed therapy with these polysaccharides in combination with existing checkpoint 
inhibitors is an interesting area to explore. In addition, these bioactive mushroom
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polysaccharides may also exhibit inhibitory activity against CTLA-4 and PD-1.It has 
been analysed in the literature that the tumours with activated immune 
microenvironment improve the antitumor activity of immune “checkpoint inhibitors” 
(Ji et al., 2012). this, in fact, was demonstrated to improve mortality rates of metastatic 
melanoma patients after treated with ipilimumab, a CTLA-1 specific antibody (Ji et 
al., 2012) In this context, immunostimulatory mushroom polysaccharides play an 
important role. These polysaccharides possess significantly high immune-enhancing 
capabilities with the least toxicity (Hattori et al., 2004, Jeong et al., 2004, Komatsu et 
al., 1969a, Zhang, 2017, Zhang et al., 2013b, Zhang et al., 2011). Pre-treatment of 
cancer patients with these immune-enhancing mushroom polysaccharides to activate 
tumour microenvironment followed by therapy with immune checkpoint inhibitors is 
expected to yield favourable outcomes for cancer patients. These studies are under 
consideration in our research group. 
2.6.2 Effect of gut microbiota on the outcomes of immune checkpoint therapy  
Recent literature strongly suggests that intestinal microbiota significantly contributes 
to the efficacy and toxicity of immune checkpoint therapy (Asmar et al., 2018). The 
checkpoint inhibitors (Ipilimumab, Nivolumab, Pembrolizumab, Durvalumab) 
employed in this therapy alter the patients gut microbiota, that in turn affects the 
efficacy of treatment (Zitvogel et al., 2017). For instance, gut microbiota such as 
bifidobacterium species improves the efficacy of treatment with PD-L1 antibodies 
(Sivan et al., 2015). Recent clinical trials (Chaput et al., 2017) demonstrate that the 
melanoma patients cured with ipilimumab (antibody specific to CTLA-4) showed a 
better survival rate if their gut microbiota was enriched with Faealibacterium species. 
Recent literature published in science (Gopalakrishnan et al., 2018, Matson et al., 2018, 
Routy et al., 2018) demonstrated the effect of the gut microbiota on the outcomes of the 
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immune checkpoint inhibition therapy in cancer. Furthermore, antibodies have been 
shown to decrease the outcomes of checkpoint inhibition therapy (Routy et al., 2018). 
The specific composition of microbiota has been shown to be associated with the 
outcomes of anti-CTLA-4 therapy (Vetizou et al., 2015). In this context, prebiotic 
mushroom polysaccharides that enhance the growth of gut microbiota are expected to 
make a significant contribution towards the efficacy of immune checkpoint inhibitors 
in cancer treatment. Treatment of cancer patients with prebiotic mushroom 
polysaccharides to improve gut microbiota, followed by therapy with suitable 
checkpoint inhibitors is expected to produce enhanced benefits. Research directed 
towards the discovery of mushroom/plant polysaccharides with prebiotic potential is 
in progress in our laboratory. 
2.7 Importance of combining immunotherapy with chemotherapy / immune 
checkpoint therapy to treat cancer 
As discussed in section 2.3, cancer patients will generally have a weak immune system. 
Immunotherapy is, therefore, a novel technique to treat cancer by amplifying or 
suppressing immune responses (Lushchak, 2014, Syn et al., 2017) Immunotherapeutic 
approaches are of two types: active and passive. These approaches are based on the 
fact that the enhanced immune system can detect, and attack tumour-associated 
molecules present on the surface of cancer cells. Active immunotherapy works by 
directly attacking tumour by targeting tumour associated molecules (Röskam et al., 
2010). However, passive immunotherapy attacks cancer cells by activating 
lymphocytes, cytokines and antibodies present in the immune system. There are 
different strategies that are used in passive immunotherapy, such as antibody-mediated 
immunotherapy, T-cell mediated immunotherapy, adoptive T-cell transfer. Antibody- 
mediated immunotherapy reduces immune suppression and target cancer cells. This 
approach has proven to be successful in treating pancreatic cancer (Banerjee et al.,
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2018, Dranoff, 2004). Conventional chemotherapeutic agents have a great tendency to 
shrink tumour cells. However, the results do not last for a long time because 
conventional chemotherapeutic agents can be toxic to both normal as well as cancer 
cells. Combining immunotherapy with chemotherapy has been shown to be superior to 
treat cancer as the improved immune system learns to fight cancer (Jeong et al., 2012, 
Jeong et al., 2004). 
Amongst various immunotherapeutic agents, mushroom constituents are known to 
exhibit excellent immune-enhancing potential. Several bioactive components from 
medicinal mushrooms have been investigated for their immunomodulatory activities 
(Hattori et al., 2004). Mushroom polysaccharides are one such class of molecules that 
are considered in the following section (Hattori et al., 2004, Jeong et al., 2012, Jeong 
et al., 2004). 
As discussed before, many mushroom/herbal polysaccharides possess significantly 
high immune-enhancing capabilities with the least toxicity. Pre-treatment of cancer 
patients with these immune-enhancing mushroom polysaccharides to activate tumour 
microenvironment followed by therapy with immune checkpoint inhibitors is expected 
to yield favourable outcomes for cancer patients. To the best of our knowledge, there 
are no literature reports published in this area. Studies directed towards the discovery 
of potent immune-enhancing mushroom polysaccharides for these applications are 
under consideration in our research group. 
2.8 A brief review of mushroom Polysaccharides and their immunomodulatory 
activities 
Some of the important immunomodulatory and anticancer mushroom polysaccharides 
and their chemotherapeutic efficacies are discussed below. 
Polysaccharide Krestin (PSK), Polysaccharopeptide (PSP) are two well-known 
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mushrooms polysaccharides extracted from C. versicolor. Both polysaccharides are 
clinically approved to be used as immunotherapeutic agents (Hattori et al., 2004). 
Numerous studies and clinical trials have proved that PSK can be used as a beneficial 
adjuvant to chemotherapy/radiotherapy for treatment of cancer (A.S and Ezeronye, 
2003, Cui and Chisti, 2003b, Hattori et al., 2004, Singdevsachan et al., 2016, Meng et 
al., 2016). It triggers innate immunity in humans to inhibit proliferation of cancer cells. 
PSK also induces enzymes in the body to eliminate free radicals; prevents DNA and 
protein damage (Zhang et al., 2012, Cui and Chisti, 2003b). Schizophyllan (SPG) is a 
polysaccharide derived from Schizophyllam commune. It stimulates immune system 
by activating immune cells such as NK cells and bone marrow cells (Komatsu et al., 
1969b, S. Dabaλ and U. Ezeronye, 2003). After extensive scientific and clinical 
investigations, SPG has been approved for its use in chemo-immunotherapy with other 
chemotherapeutic agents and this approach has shown improvement in the survival rate 
of cancer patients (Komatsu et al., 1969b). Lentinan is one of the important anticancer 
polysaccharides extracted from a mushroom Lentinula edodes. Extensive scientific 
studies have proven Lentinan to be used as an anticancer agent and acts specifically 
against Gastric and Colorectal cancer (Ina et al., 2013, Hattori et al., 2004). It improves 
the survival rate of patients when used in chemo-immunotherapy along with the known 
chemotherapeutic agents (Kozarski et al., 2012). Polysaccharide extracted from 
Ganoderma lucidum (GLP) displays antitumor activities such as cell cycle arrest, cell 
death in cancer treatment. GLP is also is known to moderate the activity of immune 
cells (Nie et al., 2013b). It is reported to decrease the potential effects of prostate cancer 
(Meng et al., 2016). C. sinensis has nutritional and medicinal benefits that includes 
improvements to circulatory, cardiovascular, immune, and respiratory systems (Chen 
et al., 2013). Polysaccharides extracted from C. sinensis have significant 
immunomodulatory, antioxidant and anti-tumour activities (Nie et al., 2013a). 
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Family name Chinese name Medicinal Use Reference 
1 Agaricus blazei 
Murrill 










Fomitopsidaceae Niu Zhang Zhi Antioxidant, cytotoxic, hepatoprotective, anti- 
inflammatory and immunomodulatory activities 




Cordycipitaceae Dong Chong 
Xia Cao 
Induced apoptosis of cancer cell, Immunomodulatory, 
Treatment of hypoglycaemic, anticancer, Anti-fibrotic 
activities 








Polyporaceae Mu Ti Ceng 
Kong Jun 










Ganodermataceae Lingzhi Anticancer via inducing cell-cycle arrest and apoptosis; 
immunomodulatory, Treatment of hyperglycaemia, 
Immunomodulatory and antioxidant activities 
(Ferreira et al., 
2015, Guo et 
al., 2009) 
9 Genus antrodia Fomitopsidaceae niu-chang- 
chih 








Hericiaceae Hou Tou Gu Anti-tumour, immune-modulating activities, Anti- 
microbial, anti-hyperglycaemic and anti- 





Hymenochaetaceae Bai Hua Rong Antioxidant activities (Ma et al., 
2012) 
13 Lentinus edodes Omphalotaceae dōnggū Antioxidant, immune-modulating and Anti-tumour 
activities 
(Smith et al., 
2002) 
14 Phellinus linteus Hymenochaetaceae song gen Anti-tumour, immunomodulatory, anti-inflammatory, anti- 









Tremellaceae pinyin Antioxidant activities, antitumor activities (Chen, 2010) 
17 Wolfiporia 
extensa 
Polyporaceae fu ling Antioxidant activities (Li et al., 
2014) 
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Owing to their numerous health benefits; it is interesting to study mushroom 
polysaccharides for their important biological activities. Two traditionally well-known 
medicinal mushrooms Ganoderma lucidum and Cordyceps sinensis are of significant 
therapeutic values. G. lucidum has traditionally been used for treating different 
ailments including hypertension, diabetes, infective diseases, neurasthenia, and cancer 
in Asian Countries (Wachtel-Galor et al., 2011b). C. sinensis has also been used 
traditionally to treat several illnesses related to the respiratory, liver, nervous system, 
cardiovascular system, also to decrease stress and, fatigue (Chen et al., 2013). All these 
health issues are related to Oxidative stress and the immune system. It is therefore very 
important to study the immunomodulatory, antioxidant and anticancer properties of 
polysaccharides from medicinal mushrooms. In this direction, this project aims to 
isolate and evaluate biological and structural characterisation of polysaccharides from 
these mushrooms. 
2.9 Selection of medicinal mushrooms for this project 
 
As discussed before, traditional medicinal mushrooms have significant therapeutic 
potential for enhancing the immune system and for the treatment of cancer. Several 
species of traditional medicinal herbs/mushrooms suitable for the treatment of cancer 
have been described and documented in the literature (Huang and Zhang, 2005, Zhu et 
al., 2004). Mushrooms chosen for this study (Table 2.2) are well documented in this 
important traditional literature and currently employed by contemporary traditional 
practitioners for the treatment of various diseases including cancer. It is therefore 
expected that these mushrooms have tremendous potential for the discovery of 
polysaccharides with immune-enhancing and anti-cancer properties and hence chosen 
for this study. 
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Family name Traditional use References 
1 Ganoderma 
lucidum 
Ling Zhi Ganodermataceae Regulate blood glucose levels, 
modulation of immune system, 
bacteriostasis, hyperlipidaemia, 
neurasthenia. 






Ophiocordycipitaceae Stimulation of energy metabolism, 
relieve mental stress, asthma, renal 
injuries, bronchitis blood pressure, 
malfunctioning of lungs. 
(Wu et al., 2014) 
 
*Medicinal Mushrooms presented in Table 2.2 were obtained in Powdered form from Concord Health. Concord Health is a Traditional Herbal 
Medicinal Clinic located in Sydney, Australia. 
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These mushrooms (Table 2.2) form important constituents in formulations to treat 
cancer and other life-threatening diseases and hence are chosen for this study. Their 
significant biological properties published in literature is discussed in the following 
paragraphs. 
Ganoderma lucidum: Ganoderma lucidum (G. lucidum) belongs to Ganodermataceae 
family and it is commonly known as Lingzhi or Reishi in Asian countries (Wachtel- 
Galor et al., 2011a). G. lucidum is a well-known medicinal mushroom in Asian 
countries and used for treatment of various diseases (Mahajna et al., 2009). G. lucidum 
consists of 26-28% of carbohydrate 3-5% fat, 7-8% protein (WachtelGalor et al., 
2011a). Literature indicates that G. lucidum displays antioxidant, immunomodulatory, 
anti-tumour, and anti-inflammatory and anti-diabetic properties (Ferreira et al., 2015, 
Jia et al., 2009). These activities displayed by G. lucidum is attributed to bioactive 
compounds like polysaccharides, proteins, phenols, and flavonoids present in this 
mushroom (Ferreira et al., 2015). 
G. lucidum polysaccharides: G. lucidum polysaccharides have excellent tendency to 
protect the liver, immune regulation, antiaging, anticancer and regulate blood sugar 
(Liu et al., 2015). It has been reported that polysaccharides with the β-D-glucan 
structure are responsible for displaying antitumor and immunomodulatory activities 
(Akramiene et al., 2007). This statement is supported by a study which shows that β- 
glucans present in GLP was able to stimulate macrophage cells to release NO (Liu et 
al., 2014). 
Cordyceps sinensis: C. sinensis is another important mushroom known for its 
traditional use to treat lung and kidney diseases in Asian countries (Chiu et al., 2016, 
Nie et al., 2013a) and is known as “Dong Chong Xia Cao”. It belongs to 
Ophiocordycipitaceae family and has been used for thousands of years in traditional 
Chinese medicine to treat cancer and other diseases (Fan et al., 2018, Sum and Ziegler,
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2016, Chen et al., 2013, Nie et al., 2013a). Water-soluble polysaccharides from natural 
and cultured C. Sinensis possess immune regulation and antitumor function. C. 
Sinensis polysaccharides (CSPs) play an important role in relieving renal failure caused 
by fulgerizing kidney (Nie et al., 2013a, Wang et al., 2010). CSPs have also been 
shown to possess the immuno-potentiating ability and promote nitric oxide production 
and stimulate macrophages (Wang et al., 2017). 
Owing to their tremendous therapeutic value demonstrated in the literature; this 
research aims to isolate, purify, characterise and to investigate biological and structural 
properties of polysaccharides from two novel medicinal mushrooms (Coriolus 
versicolor and Ganoderma lucidum) that are currently used by contemporary 
traditional practitioners. 
2.10 Aims and objectives of this project 
Briefly, the main aims and objectives of this project are: 
 Extraction and purification of polysaccharides from Coriolus versicolor and 
Ganoderma lucidum 
 Investigation of their antioxidant, immunomodulatory, prebiotic, and anti- 
cancer activities 
 Structural characterisation of active polysaccharides 
Discovery of novel polysaccharides with immune-enhancing, prebiotic and anti-cancer 
properties, is expected to lead the way towards developing strategies to enhance the 
efficacy of immune checkpoint therapy described in section 2.6. In this context, both 
immune-enhancing and prebiotic properties are extremely important. Development of 
novel immune-enhancing formulations by combining most active polysaccharides is 
also another important outcome of this research. 
To fulfil the above aims and objectives in an effective manner, it is necessary to 
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develop efficient research methodologies. In this direction, a detailed review of the 
methods available in the literature for extraction, purification and biological 
characterisation has been carried out. These methods are outlined and critically 
evaluated in the following sections. 
2.11 Methods of extraction of polysaccharides from plants/mushrooms 
 Several methods are available in the literature for this purpose and the most important 
ones are hot water extraction, microwave-assisted extraction (MAE) and Ultrasonic- 
assisted extraction (UAE). These are discussed below. 
2.11.1 Hot water extraction 
 
Hot water extraction is a well-known technique for polysaccharides from plants and 
mushrooms because of its safe and environment friendly (Kozarski et al., 2012, Zhang 
et al., 2012, Zhang et al., 2014, Zhang et al., 2007). High temperature can accelerate 
the extraction of polysaccharides from cell walls. 
Traditionally, the hot water extraction method involves medicinal plant 
material/mushrooms to be powdered in large quantity and then homogenized to sustain 
consistency. Each grounded sample is then mixed with water in a ratio (1:5 Sample: 
water) and subjected to hot water extraction either by autoclaving at 121°C (Zhang et 
al., 2012) or by direct heating. The mixture is then filtered, and the filtrate is 
precipitated overnight with 95% aqueous alcohol (Ethanol) (1:4; filtrate: ethanol) at 
4°C to remove non-polar compounds and obtain biopolymers. Samples containing 
biopolymers (polysaccharides and proteins) are then centrifuged and collected (Zhang 
et al., 2012, Zhang et al., 2014). The mixture is then stored at -80°C until frozen and 
then freeze-dried (Jeong et al., 2012, Jeong et al., 2004, Zhang et al., 2012, Zhang et 
al., 2013b). Although the hot water extraction method is cost-effective and simple, it 
is time-consuming and involves high extraction temperatures that may result in
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degradation, structural modification and can affect the yield of polysaccharides. 
The large volume of research related to polysaccharide extraction optimisation has led to 
the choice of parameters that are shown to be of importance in maximising the extraction 
yield (Fan et al., 2018, Huang et al., 2018, Jia et al., 2009, Li et al., 2001, Meng et al., 
2013, Zhang et al., 2012, Zhang et al., 2014). These parameters can effectively contribute 
to modifying the yield of polysaccharides. Extensive research validates that optimizing 
these independent extraction factors like temperature, time and solvent-solute ratio that 
can alter the extraction yield of polysaccharides. The temperature for extraction is a key 
parameter that can affect extraction efficacy and selectivity (Yang et al., 2013, Ying et 
al., 2011). Research reveals that the extraction yield of a mushroom polysaccharide 
increases on increasing the temperature (Yang et al., 2013). The reason behind this might 
be because of temperature and high pressure affects the surface tension and increases the 
diffusion rate from solid to liquid and can increase the cell wall damage (Carr et al., 
2008). The solvent-solute ratio is also the main parameter for improving the quality of 
extract. Above discussion related to optimising the parameters involved in extraction 
significantly affect the yield of polysaccharides. It would be interesting to find out 
optimum temperature, time and solvent-solute ratios by performing a different set of 
experiments. However, in this research year, time and fund ing  are limited therefore, 
the extraction of polysaccharides was carried out by classical hot water autoclave 
extraction method. 
2.11.2 Microwave-assisted extraction of polysaccharides  
Microwave-assisted extraction (MAE) is another widely used method for 
bioactive compounds such as polysaccharides (Chen et al., 2005, Zhao et al., 
2010). This technique offers many advantages for extracting biopolymers such as 
the reduction of extraction time and solvent consumption and improve sample.
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yield (Amutha Gnana Arasi et al., 2016, Le et al., 2019b, Liu, 2015, Llompart et 
al., 2019, Wen et al., 2015). Moreover, using this method, multiple samples can 
be extracted simultaneously (Llompart et al., 2019). Microwaves are Non-
ionizing electromagnetic radiation and the mechanism involved in microwave 
extraction is ionic conduction and dipole rotation which is responsible for heating 
of substance (Tatke and Jaiswal, 2011). Microwaves target minute of moistness in 
cells of dried plant material and result in evaporation that creates high pressure on 
the cell wall leading to its breakdown and facilitating extraction (Tatke and Jaiswal, 
2011). The active constituents leach out from the cell wall and hence increase the 
yield of bioactive compounds. Literature displays the importance of combining hot 
water extraction with microwave heating (Zhao et al., 2010, Zhang et al., 2012, Zhang 
et al., 2014). It can improve the yield of extracted polysaccharides, and other 
phytochemicals (Zhao et al., 2010, Zhang et al., 2012, Zhang et al., 2014). Although 
MAE is fast, consumes less solvent and efficient in terms of yield than traditional 
methods of extraction of polysaccharides, a higher power of microwaves can potentially 
cause structural modification of polysaccharides (Zhang et al., 2012, Zhang et al., 2014). 
It is therefore important to implement this technique with great attention and limit 
microwave power (Zhao et al., 2010). Extensive research has been carried out to optimize 
the extraction conditions that affect the yield such as temperature, time of extraction, 
solvent to solute ratio and pH of the solution using response surface methodology 
(Amutha Gnana Arasi et al., 2016, Le et al., 2019b, Liu, 2015, Llompart et al., 2019, Wen 
et al., 2015). 
2.11.3 Ultrasonic-assisted extraction (UAE) of polysaccharides  
Like microwave-assisted extraction, an ultrasonic-assisted extraction is also an effective 
approach for extracting polysaccharides as it takes less extraction time and produces a 
high extraction yield (Cui et al., 2018, Ying et al., 2011). This technique is widely used
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due to its easy operation (Zhao et al., 2015, Aguiló-Aguayo et al., 2017). The principle 
of Ultrasonic-assisted extraction is similar to Microwave-assisted extraction, i.e. the cell 
wall is destroyed by ultrasound radiations that result in leaching out bioactive 
constituents from ruptured cells without modification of the structure of the 
polysaccharides. 
Ultrasonic assisted extraction is carried out by dissolving finely powdered mushroom 
samples into deionised water. The mixture is then sonicated with an ultrasonic processor 
at ultrasound amplitude levels of 120 W to 300W for 5 to 40 minutes at a range of 
temperatures 25°C to 70°C (Aguiló-Aguayo et al., 2017). After sonication, the extract 
is allowed to cool down at room temperature and centrifuged and the supernatant is then 
mixed with 80% ethanol to remove small molecules from the supernatant (Chen et al., 
2012, Aguiló-Aguayo et al., 2017). The yield of extracted bioactive compounds is 
significantly affected by varying the parameters such as temperature, time of extraction, 
ultrasonic power and solute-solvent ratio (Aguiló- Aguayo et al., 2017, Chen et al., 2012, 
Chen et al., 2017a, Wang et al., 2016, Yılmaz and Tavman, 2015). The yield of extracted 
polysaccharides can be improved by optimising these parameters. Research conducted 
by Chen et al., 2012, to optimise the extraction yield of polysaccharides by ultrasonic 
assisted  extraction with sample concentration 30g/l, 60°C and at frequency 40kHz 
gave maximum yield (36.77±1.76%) at 500W in 60 minutes of extraction time. 
Ultrasonic assisted extraction in combination with microwave-assisted extraction is 
shown to be the best method for extraction of bioactive components, however, this 
method is relatively time-consuming (Bagherian et al., 2011). 
In general, MAE and UAE methods have improved time-efficiency, reduced solvent 
consumption and improved yield of extracted polysaccharides (Yang et al., 2008, Ying et 
al., 2011). However, because of cost-efficiency, simplicity, limited resources and time, 
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the classical hot water extraction procedure was employed for the extraction of 
polysaccharides from medicinal mushrooms in this project. 
2.12 Deproteination of polysaccharides 
Few methods such as trichloroacetic acid method, hydrochloric acid method and 
sevag method are common methods that are used for deproteination of 
polysaccharides (Zhang et al., 2017b). However, Sevag method is the mildest 
technique to remove unbound proteins from polysaccharides (Staub, 1965). 
Sevag reagent is prepared by mixing butanol in chloroform in a ratio 1:4 vol/vol. 
The unbound proteins are denatured by an organic solvent to an insoluble 
protein-chloroform gel-like substance which forms the lower layer upon 
centrifugation and can be removed using separation funnel. This process must 
be repeated several times to completely remove protein from samples. Alcohol 
especially butanol is used to prevent foaming of the mixture on shaking or 
vortexing and it helps in the separation of the layers. This method results in low 
polysaccharide retention rate i.e. low polysaccharide yield due to the need for 
repeating extraction steps (Li et al., 2019). 
2.13 Purification of polysaccharides 
 
Several methods are available in the literature for the separation of polysaccharides from 
the extracted mixture and the most suitable method is size exclusion Chromatography. 
This method isolates polysaccharides based on their hydrodynamic radius and molecular 
masses. Some details of the method are described below. 
2.13.1. Size exclusion chromatography 
 
Chromatography is a widely used technique to isolated mixtures into pure components. 
In general, in chromatography, a fluid (sample) passes through a stationary phase. A 
compound with strong interactions in the given mixture and stationary phase, will take 
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longer to pass through the whole column. On the contrary, a compound with fewer 
interactions will move with the same velocity of the mobile phase. This is how 
chromatography helps in separation of the different components of a mixture depending 
upon the binding affinity of a component with a stationary phase. 
In particular, size exclusion chromatography is a separation technique for separating 
molecules in solution based on their size and molecular weight. In this technique, the 
stationary phase is a polymeric matrix with a distribution of pore sizes and the mobile 
phase contains analytes and are separated with respect to their sizes. Larger molecules 
will not fit into most of the pores and will elute first. Smaller molecules tend to penetrate 
most of the pores of the polymer matrix and will take longer time to elute. A detailed 
description of the working procedure of SEC is discussed in chapter 3. 
2.14 Determination of chemical constituents of polysaccharides 
Total sugar content: Phenol-sulphuric assay can be employed to analyse total sugar 
content in polysaccharides, this method is developed by (DuBois et al., 1956). It is based 
on the principle of degradation of sugar molecules in the presence of an acidic medium. 
Generally, with heat and strong acid (Conc. H2SO4), sugar molecules breakdown and 
forms furan derivatives such as formaldehyde and hydroxymethyl furaldehyde 
(Brummer and Cui, 2005). Initially, dehydration occurs and it is followed by the 
formation of furan derivatives. These furan derivatives condense themselves with 
phenolic compounds to give yellow-orange colour. Absorbance for these derivatives can 
be measured at 492nm in UV spectrophotometer (Brummer and Cui, 2005). The chemical 
reaction involved in this method is given by:
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The protein content of polysaccharides: Lowry and Bradford's assays are the two most 
used methods for quantification of protein composition in mushroom polysaccharides 
(Lowry et al., 1951, Redmile-Gordon et al., 2013, Zhang et al., 2012). This method is 
suitable for analysing even a very small amount of protein in the sample (0.01 – 1.0 
mg/ml). This assay is based on the fact that in basic medium reaction occurs in two steps, 
first is the Biuret reaction (shown in figure): that involves reduction of Cu2+ and binds 
to protein to form a Cu1+ peptide complex, and second step is reduction of the Foline-
ciocalteu reagent by peptide complex formed (Redmile-Gordon et al., 2013, Smith et al., 
1985). 
 
2.15 Measurement of Biological activities of polysaccharides 
 
Several biological properties including antioxidant, immunomodulatory, prebiotic and 
anticancer activities of polysaccharides were measured in this research. Principles and 




2.15.1 Antioxidant capacities of bioactive compounds 
 
Free radicals are produced during metabolic processes occur in the body (Lushchak, 
2014). In addition to this, Continuous environmental stress such as exposure to pollution 
and UV radiation is also another major reason of formation of free radicals in the body. 
Few examples of free radicals are superoxide anion (O2
•ˉ), Hydroxyl radical (OH•), 
hydrogen peroxide (H2O2). 
Oxidative chain reactions cause oxidative stress and their removal can help human body 
from serious health problems. Medicinal mushrooms and their polysaccharides are 
known to have significant antioxidant properties (Alam et al., 2013, Chen et al., 2017b, 
Ferreira et al., 2015, Jia et al., 2009, Kang et al., 2019, Le et al., 2019a, Li et al., 2011b). 
There are many assays in the literature for determining antioxidant capacities of 
bioactive compounds by employing chemical radical species, such as ABTS₊•, OH•, 
DPPH radicals for analysing antioxidant activities (Alam et al., 2013, Chen et al., 2017b, 
Ferreira et al., 2015, Jia et al., 2009, Kang et al., 2019, , Le et al., 2019a, Li et al., 2011b). 
These methods evaluate the ability of polysaccharides to scavenge these chemical 
radicals. 
In this study, the antioxidant activity of medicinal mushroom polysaccharides was 
analysed by using the DPPH, ABTS and OH radical scavenging methods in vitro. The 
theory and basic principles of these approaches are briefly described in the following 
sub-sections. 
Principles of ABTS radical scavenging assay: ABTS (2,2'-azino-bis (3-
ethylbenzothiazoline-6- sulphonic acid) radical scavenging assay is sensitive, easy, and 
most commonly used method for analysing antioxidant capacity of bioactive compounds 
such as polysaccharides (Zhang et al., 2013a). ABTS is a stable synthetic free radical and 
in the presence of a strong oxidising agent (potassium persulphate) transforms into its 
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radical cation and forms a blue-green coloured solution that has a strong absorption at 
734nm (Li et al., 2011a, Zhang et al., 2012). The figure shown below is an electron 
transfer mechanism (Hernández-Rodríguez et al., 2019, Lee et al., 2016). The 
discolouration of the reaction mixture after addition of ABTS+˙ to the polysaccharide 




Principles of DPPH free radical scavenging activity 
Another similar colorimetric method for measuring radical scavenging capacities of 
bioactive compounds employs DPPH (1, 1-diphenyl-2-picrylhydrazyl) free radical 
scavenging assay. DPPH radical stabilises by accepting an electron and becomes 
diamagnetic (Blois, 1958, Nithya and Madhavi, 2017). After reacting with reducing 
agents (e.g. polysaccharides), the solution loses colour, depending on the number of 
electrons taken up (Blois, 1958, Zhang et al., 2012). Polysaccharides can donate 
electrons or hydrogen atoms results in the conversion of DPPH radical (which is purple) 
into the non-radical form 1,1-diphenyl-2-picrylhydrazine (which is yellow) (Nithya and 
Madhavi, 2017). The basic reaction involved in this assay is represented below. This 
method is very simple and fast and is highly suitable for analysing radical scavenging 




Principles of OH radical scavenging activity  
As discussed earlier OH radicals are biologically significant reactive species and the 
conditions of oxidative stress in the body, these radicals have the potential to damage 
DNA and other biomolecules. Hence, capping the formation of OH radical can control 
further DNA damage and carcinogenesis. In this research, the OH radical scavenging 
activity of polysaccharides is determined with the assay described in the literature (de 
Avellar et al., 2004) with some modifications. OH radicals can be generated from H2O2 
using Fenton reaction. This reaction in the presence of transition metal ions such as Fe 
(II) generates OH radicals. 
Fe2+ chelating assay 
Maintaining a correct balance of Fe2+ ions in the body is a delicate process that is 
extremely important. This assay is employed to determine the affinity of polysaccharides 
to form a complex with Fe2+. Firstly, polysaccharides and Fe2+ (FeCl2) are mixed to form 
Fe-polysaccharides complex. Ferrozine is a good chelator, therefore, ferrozine is added to 
the reaction mixture to trigger the competition between polysaccharides and ferrozine 
for chelation with Fe2+ (Li et al., 2011a). The absorbance of the red coloured ferrozine-
Fe2+ complex is determined using a UV spectrophotometer at 562 nm (Zhang et al., 
2012). 
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2.15.2. Immunomodulatory activities of polysaccharides 
 
The ability of bioactive polysaccharides to activate macrophage cells that results in the 
production of immune-enhancing cytokines is a measure of their immunostimulatory 
capacity. Production of cytokines such as TNF-α and IL-6 provides a good measure of 
the immunomodulating capacity of bioactive compounds (Ayeka et al., 2016, Wu et al., 
2014, Zhang et al., 2013a, Zhang et al., 2012, Zhang et al., 2018b). In this method, 
macrophage cells are cultured to reach confluency and these cells are then treated with 
polysaccharides and incubated overnight. Macrophages produce cytokines based on the 
immunostimulatory abilities of the polysaccharides. Commercial ELISA kits are 
employed to measure the quantities of TNF-α and IL-6 produced. TNF-α and IL- 6 
standards are used to build a standard curve from which the quantities produced by 
sample treatment can be evaluated. The amount of cytokine production is directly related 
to the immunomodulating capacities of polysaccharides. 
2.15.3. Prebiotic activities of polysaccharides 
The ability of polysaccharides to act as a carbohydrate source for the consumption of 
probiotic bacteria like Lactobacillus and Bifidobacteria. L. acidophilus, L. rhamnosus, B. 
animalis and B. lactis and other species of gut bacteria is related to their prebiotic 
capacity (Singdevsachan et al., 2016, Thambiraj et al., 2015). When the gut bacteria 
consume mushroom polysaccharides and display a healthy growth, the bacterial growth 
density increases, and certain acids are secreted. Increase in the turbidity of the medium 
indicates bacterial growth and a decrease in the pH of the growth medium indicates 
fermentation of polysaccharides by these bacteria. In fact, the fall in pH of the medium 
with respect to time provides a direct measure of prebiotic abilities of the polysaccharides 
(Singdevsachan et al., 2016, Thambiraj et al., 2015). 
2.15.4. Anticancer activities of polysaccharides 
Cytotoxic abilities of polysaccharides are measured from their ability to kill cancer cells 
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(MCF-7 cells (human breast adenocarcinoma, ATCC Cat. No. ATCCÒ HTB- 22TM), 
PC3 cells (human prostate cancer, ATCC Cat. No. ATCC® CRL-1435TM), and DU145 
cells (human prostate cancer, ATCC Cat. No. ATCCÒ HTB-81TM) (Zaman et al., 2019). 
Cancer cell lines are cultured to reach a certain confluency and these cells are treated 
with polysaccharides and incubated overnight. Cell viability measurements of the treated 
cells employing MTT test provides information on cytotoxicity of polysaccharides 
(Ayeka et al., 2016, Shah et al., 2013, Zaman et al., 2019, Zhang et al., 2018a). Lower 
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                  Chapter – 3  




3.1.1. Procurement of traditional Chinese mushrooms for the research project 
The medicinal mushrooms studied for the research project was provided by Dr Eric 
Wong. Dr Wong is a traditional Chinese doctor at Concord health in Sydney. Mushrooms 
provided were in fine powdered form. Samples were stored in the refrigerator at 4°C in 
the laboratory. These mushrooms are used as medicine for treating different ailments in 
Concord health Sydney. 
3.1.2. Chemicals & reagents 
Chemicals  
ABTS (2,2’-azino-bis (3-ethylbenzoazothiazoline-6-sulphonic acid), DPPH (2,2- 
diphenyl-1-picrylhydrazyl), potassium persulphate, Ascorbic acid, PBS buffer, 
phosphate buffer, ferrous chloride, Ferrozine (sodium 4-[3-pyridin-2-yl-5-(4- 
sulfophenyl)-1,2,4-triazin-6-yl] benzenesulfonate), copper sulphate, bovine serum 
albumin, Sodium citrate, sodium hydroxide, Folin ciocalteau reagent, sodium carbonate, 
conc. Sulphuric acid, glucose, phenol. RAW 264.7 mouse macrophages cell lines, 
Tumour Necrosis Factor (TNF-α) and Interleukin (IL-6) (mouse) ELISA standards were 
purchased from Sigma Aldrich Australia. 
Solvents 




3.2.1 Extraction of crude polysaccharides from traditional medicinal 
mushrooms 
Medicinal mushrooms were supplied in fine powder and homogenised form. Hot water 
extraction is reliable, efficient, cheap and most commonly used method to extract 
polysaccharides from mushrooms (Nie et al., 2011, Zhang et al., 2007) therefore, this 
method was employed to extract water-soluble compounds (polysaccharides) from 
medicinal mushrooms. 20 gm of each mushrooms sample was dissolved in 100ml 
deionised water and autoclaved for an hour at 121°C (Zhang et al., 2012). The mixture 
was then let set to the room temperature and then filtered with Buchner funnel. Ethanol 
was then added to filtrate in the ratio (1:4; filtrate: ethanol) and left at 4°C overnight for 
precipitation (Zhang et al., 2014). Polysaccharide samples were then centrifuged for 20 
minutes at 10,000 rpm and precipitate comprising water-soluble polysaccharides were 
collected and dissolved in deionised water (Zhang et al., 2014). The solution was 
refrigerated at -80°C until frozen and then freeze-dried in a freeze dryer (Christ Alpha 1-
4, B. Braun Biotech International) (Jeong et al., 2012, Jeong et al., 2004, Zhang et al., 
2012, Zhang et al., 2013b). Samples were then transferred to the sample vials and 
refrigerated at -30°c until further examination. 
3.2.2 Analysis of chemical composition 
 
Polysaccharides are large molecular weight carbohydrate molecules containing a large 
number of mono-sugar units. Also, some of the very important mushroom 
polysaccharides in literature are found to have attached protein molecules or different 
protein chains and they are called polysaccahropeptides (Cui and Chisti, 2003). 
Chemical composition of mushroom polysaccharide was analysed as follows:
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3.2.2.1 Total sugar analysis 
 
Sugar content in polysaccharides was analysed by phenol sulphuric assay. This assay 
was developed by (DuBois et al., 1956). The phenol-sulphuric acid assay is a reliable, 
cheap and sensitive method for analysis of sugar such as polysaccharides, glycolipids, 
glycoproteins and oligosaccharides (Masuko et al., 2005). Simple sugars such as 
oligosaccharides, polysaccharides when treated with phenol and concentrated sulphuric 
acid, gives a stable orange-yellow colour (DuBois et al., 1956). This assay was employed 
with slight modifications. To begin with, 50 μl of the polysaccharide sample at different 
concentrations was added to the test tube and 100 μl of 5% phenol was added. To start 
the reaction 500 μl of conc. H2SO4 was pipetted into the test tube and vortexed (Zhang, 
2017). Absorbance was then measured at 492nm in a UV spectrophotometer 
(SpectrostarNano BMG LABTECH). Glucose at different concentrations (1000µg/ml, 
500, 250, 125, 62.5, 31.25, 15.66, 7.83µg/ml) was used as standard. All measurements 
were taken in triplicate. A standard curve shown below against concentration and 
absorbance was plotted and standard curve equation (y = 0.0026x + 0.5216) was used to 
calculate the total sugar content of each mushroom polysaccharides. All measurements 














Fig3.1: Standard plot of glucose for phenol-sulphuric assay 
Concentration (µg/ml) 








y = 0.0026x + 0.5216 















3.2.2.2 Protein analysis 
Lowry assay with slight modifications was implemented to analyse the protein 
composition of mushroom polysaccharides (Lowry et al., 1951, Zhang et al., 2012). This 
method is suitable for analysing even a very small amount of protein in the sample (0.01 – 
1.0 mg/ml) (Lowry et al., 1951). This assay is based on the fact that CuSO4 in basic 
medium forms a strong chelate with peptide bonds in the presence of sodium/potassium 
tartrate. Folin-Ciocalteau reagent, a strong oxidizing agent when reacts with CuSO4, Cu 
oxidize from Cu+1 to Cu+2 and form molybdenum blue (Legler et al., 1985). 
To perform this assay firstly, three different reagents were prepared; Reagent A: CuSO4 
and Sodium citrate, Reagent B: sodium carbonate and sodium hydroxide and Reagent C: 
Reagent A+ Reagent B (Zhang, 2017). Then, 200 μl of the polysaccharide sample was 
taken in a test tube. To this 1ml of Reagent C was added and mixed and then kept for 10 
minutes. Then 100μl of 1N Folin-Ciocalteu reagent was added to it and shaken 
vigorously (Zhang, 2017). The absorbance was measured at 750 nm in a 
spectrophotometer (SpectrostarNano BMG LABTECH) after incubating the reaction 
mixture for 30 mintues. Bovine Serum Albumin at different concentrations (1000 µg/ml, 
500, 250, 125, 62.5, 31.25, 15.66, 7.83µg/ml) was used as a standard. The standard curve 
was plotted against concentration and absorbance. The standard equation y = 0.0015x + 
0.0987 was then used to calculate protein concentration in polysaccharide samples. All 



















Fig 3.2: Standard plot for Lowry assay 
 
3.2.3 Deproteination of polysaccharide samples 
Sevag method is the softest technique to remove proteins from polysaccharides (Staub, 
1965). A Sevag reagent can be prepared by mixing n-butanol and chloroform in 1:4 
vol|vol ratio (Seedevi et al., 2013). To perform this assay, 6mg/ml concentration of the 
sample was taken and Sevag reagent, 1/5 of the total volume of sample was added to it 
and shaken vigorously on a magnetic stirrer for 20 minutes (Zhang, 2017). After 20 
minutes of shaking, the mixture was then centrifuged for 10 minutes at 8000rpm (Sigma 
3-16 PK, John Morris scientific pty ltd). The upper layer was taken and the whole 
procedure was repeated until whole protein was completely removed. After completion 
of the removal, 4 volumes of ethanol were added to the treated polysaccharide fraction 
and left overnight at 4°C for precipitation (Seedevi et al., 2013, Zhang, 2017). After 
precipitation, polysaccharides fractions were centrifuged for 20 minutes at 10,000rpm. 
The precipitates were dissolved in 50 ml of deionised water and kept at -80°C for at least 
5 hours. Samples were then freeze-dried and kept at -30°C freezer until further 
investigation. 
3.2.4 Purification of polysaccharides using Size Exclusion Chromatography 
Bioactive compounds can be purified or fractionated by using different separation 












y = 0.0015x + 0.0987 
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chromatography (HPLC) and ion-exchange chromatography, thin-layer 
chromatography (TLC). This project involves the purification of Bioactive compounds 
were purified by using size exclusion chromatography. 
3.2.4.1 Home packing of large size exclusion column for quantitative separation 
of mushroom polysaccharides 
Size-exclusion chromatography column XK 26 (2.4 x 99 cm) was available in the lab 
and Sepharose CL-6B gel was purchased from Sigma Aldrich for developing the column. 
After decanting ethanol, the slurry was prepared by adding 75% water to the gel 
(Healthcare, Zhang, 2017). The slurry was degassed for a minimum of 8 hours before 
packing. Top and bottom adapter of the column were injected with ethanol to remove 
air. The gel was poured to the column after inserting end piece (or adapter at the bottom). 
After pouring the whole slurry, distilled water added on the top of the gel and fill the 
reservoir to the top with eluent or distilled water and reservoir cap was inserted at an 
angle to avoid entering any air bubble into the column. The column was then connected 
to a pump at flow rate 0.5ml/min until gel had reached a constant height (Zhang, 2017). 
The performance of the column was investigated using dextran standard of known 
molecular weight (2000kDa, 70kDa, 10kDa & Glucose). The plot of performance of size 
exclusion chromatographic column is given in chapter 4, Fig 4.5. 
3.2.5 Determination of molecular weights of polysaccharide fractions 
 
Standard dextran with different molecular weights including 2000kDa, 450kDa,  
150kDa, 70kDa, 40kDa, 10kDa and glucose were used for standard curve plot. 10 mg/mL  
dextrans with molecular weight such as 2000kDa, 70kDa and glucose were mixed and 
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injected to the column with flow rate 0.5ml/min (Jeong et al., 2012, Jeong et al., 2004, 
Zhang et al., 2012, Zhang et al., 2014, Zhang et al., 2007). The elution volume was 
collected in sample tubes in a fraction collector. Similarly, other dextrans such as 
450kDa,10kDa in one set and 40kDa in another set with the same concentration were 
injected to the column. The standard dextran elution profile shown below was analysed 
by the phenol–sulphuric acid method (DuBois et al., 1956, Jeong et al., 2012, Zhang et al., 
2014). A standard curve with straight-line equation y = -0.2349x + 1.5535 was plotted 
using the elution profile. Mushroom polysaccharides of concentration 20mg/ml were 
then injected to the column and collected in a fraction collector. Sugar concertation of 
each sample was then measured with the phenol-sulphuric acid method. The significant 
fractions were collected and freeze-dried. Molecular weights of the fractionated 
polysaccharide were estimated on the basis of the standard curve. The sugar profile and 
standard curve of dextrans are given below: 
The entire process of extraction, deproteination and purification of mushroom 












Fig 3.3 Flow chart for the extraction, deproteination and purification of mushroom polysaccharides of 
polysaccharides 
 
3.2.6 Structural characterisation of active polysaccharides 
 
Structure of polysaccharides is the most important feature to determine their functions. 
By Combining spectroscopic, chromatographic, and chemical techniques, the structure 
of a biopolymer can be determined. Spectroscopic techniques such as Nuclear magnetic 
resonance (NMR) and Fourier transform infrared spectroscopy (FT- IR) is known to be 
the most appropriate means to determine the detailed tertiary structures of 
polysaccharides. 
3.2.6.1 Fourier transforms infrared (FT-IR) spectroscopy 
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Centrifugation (10,000 rpm for 20 min) 
Freeze dry 
Autoclaving (121°C for 2h) 
Centrifuging (10,000rpm for 20 min) 
Crude biopolymer 
• Crude biopolymer dissolved in water 
• Treated with Sevag reagent 
• Precipitation with 95%EtOH (1:4 vol:vol overnight) 
• Centrifugation (10,000 rpm for 20 min) 
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Polysaccharides Fractions 
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vibrations and is a very useful technique to study functional groups. This technique can 
be used for determining structural details such as type of monosaccharides, glycosidic 
linkages, and functional groups of polysaccharides. Purified polysaccharide fractions 
were characterized by FTIR spectroscopy using TENSOR II FTIR Spectrometer 
(BRUKER) at room temperature 25°C. The scanning of spectra was taken between 4000 
cm−1 and 450 cm−1 with the resolution of 4 cm−1 (Subramanian and Rodriguez-Saona, 
2009, Zhang, 2017, Zhang et al., 2018a, Zhang et al., 2018b, Zhang et al., 2014). FTIR 
instrument scan sample and analyse its chemical properties using infrared radiations. The 
FTIR signals IR radiation of about 10,000 to 100 cm-1 through a sample, only a part of 
radiations will be observed by the sample. These absorbed radiations transformed into 
rotational and/or vibrational energy by the test molecules (Subramanian and Rodriguez-
Saona, 2009, Zhang et al., 2011a, Zhang, 2017, Zhang et al., 2018a). A range from 4000 
cm-1 to 400cm-1, the resulting signal in the form of spectrum displayed at the detector 
that represents a molecular fingerprint of the test sample. Each chemical structure will 
have a unique spectral fingerprint, which makes FTIR a great device for molecular 
determination. 
3.2.7 Evaluation of biological activities of mushroom polysaccharides 
 
In literature, polysaccharides extracted from mushrooms show biological activities, for 
instance, antioxidant, immunomodulatory, anticancer and antibacterial properties 
(Zhang et al., 2018b, Zhang et al., 2013b, Zhang et al., 2011b, Zhang et al., 2017). 
Therefore, it will be interesting to analyse the biological activities of polysaccharides 
extracted from G. lucidum, G. lucidum spores and C. sinensis. 
3.2.7.1 Antioxidant activities 
 
Antioxidant activities of bioactive compounds can be measured by using synthetic 
radicals such as ABTS˙+, DPPH and biological radicals such OH radicals. Antioxidant 
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agents can also be a good chelating agent and it can be determined by using chelating 
methods e.g. iron-chelating assy. 
 
3.2.7.1.1 ABTS (2,2′-Azinobis-(3-Ethylbenzthiazolin-6-Sulfonic Acid) radical 
scavenging assay 
Antioxidants responses involve faster reaction kinetics therefore ABTS˙+ scavenging 
activity is a very sensitive technique to identify the antioxidant activity of bioactive 
compounds (Chanput et al., 2016). To perform this assay, 7mM of ABTS and 2.45 mM 
potassium persulfate was added and mixed to produce ABTS radical cation (ABTS˙+) 
and mixture was kept in the dark and at room temperature for overnight before use 
(Zhang et al., 2013a, Li et al., 2011, Zhang et al., 2014). ABTS˙+ radical cation was then 
diluted using 0.1M PBS buffer (pH 7.0 - 7.4) to bring its absorbance in absorbance 
(0.70±0.02 - 0.70±0.05) in the given range. Ascorbic acid at different concentrations 
(400µM, 200, 100, 80, 60, 40, 20µM) was used as standard. 100µl of ascorbic acid 
(prepared in 60% methanol), sample and negative control at different concentrations 
(1000µg/ml, 500, 250, 125, 62.5, 31.25, 15.63, 7.81). were taken in the test tubes and 1ml 
ABTS˙+ was added to each test tube. After incubation of half an hour in dark at room 
temperature, the absorbance was measured in a spectrophotometer (Thermo scientific 
Genesys 10S UV-VIS spectrophotometer) at 734nm. ABTS was used as blank. A graph 
with straight-line equation Y = mx+c was plotted for a standard against concentration 



















Fig 3.2.6: Standard plot of vitamin C 
 
The equation for calculation of % radical scavenging activity 
 
 
% 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 = 








Where A0 is Absorbance of blank and A is the absorbance of the sample. All 
measurements were performed in triplicate to minimise error. 
 
3.2.7.1.2 OH radical scavenging assay 
 
OH˙ radical scavenging assay was used with a slight modification (de Avellar et al., 
2004). To perform this assay, 50 μl of the sample at various dilutions (1000µg/ml, 500, 
250, 125, 62.5, 31.25, 15.63, 7.81 (prepared in 0.1 M sodium phosphate buffer, pH 
7.4) were pipetted to a 96-well microplate. 50 μl of both 3 mM 1,10-phenanthroline (in 
phosphate buffer) and 3 mM FeSO4 (prepared in deionised water) was then mixed. 50 
μl of 0.01% aqueous H2O2 was then added to each well to initiate the reaction (Zhang 
et al., 2012). The plate containing reaction mixture was then covered and incubated in 
dark at 37 °C for 1 h in shaker incubator (Thermoline scientific Orbital shaker 
incubator). The absorbance was measured using a spectrophotometer (SpectrostarNano 
BMG LABTECH) at 536 nm. The absorbance of blank was measured 
0 50 100 150 200 250 
Concentration µg/ml 
y = -0.0022x + 0.5839 



















with a reaction mixture containing distilled water, FeSO4 and 1,10-phenanthroline. The 
absorbance for control was measured with a reaction mixture containing distilled 
water, FeSO4, 1,10-phenanthroline and 0.01% aqueous H2O2. All measurements were 
performed in triplicate to minimise error. 
 
𝐀𝐒𝐚𝐦𝐩𝐥𝐞    − 𝐀𝐂𝐨𝐧𝐭𝐫𝐨𝐥 
% 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲 = 
𝐀𝐁𝐥𝐚𝐧𝐤 − 𝐀𝐂𝐨𝐧𝐭𝐫𝐨𝐥 
× 𝟏𝟎𝟎 
 
Where Asample is the absorbance of the sample, Acontrol is the absorbance of the control, 
Ablank is the absorbance of a blank. 
3.2.7.1.3 Fe2+ chelating activity 
 
Fe2+ chelating activity of polysaccharide samples were analysed by the method 
provided by (Decker and Welch, 1990, Wang et al., 2008, Zhang, 2017) with slight 
modifications. Ethylenediaminetetraacetic acid (EDTA) was used as a positive control 
for comparing the activity of polysaccharides in this assay. 100µl of EDTA at different 
concentration (50µg/ml, 25, 12.5, 6.3, 3.1, 1.5) was mixed with 10µl of 1mM FeCl2 to 
form Fe-polysaccharide complex (Umamaheswari and Chatterjee, 2007, Wang et al., 
2008). To this, 10µl of 5mM Ferrozine was added and mixed to initiate the competition 
between EDTA and Ferrozine for chelating Fe2+ and then incubated for about 10 
minutes. The absorbance was measured at 562nm using UV spectrophotometer 
(SpectrostarNano BMG LABTECH). The graph was plotted against concentration and 
absorbance. The same procedure was repeated for polysaccharide samples. The 
absorbance for blank was also calculated by the whole reaction mixture by adding 
distilled water instead of sample. The equation given below was used to calculate the 
chelating activities of the polysaccharide 
 
 
% 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 = 







Where A is the absorbance of Sample and A0 is the absorbance of Blank. All 
measurements were done in triplicate to minimise error. 
 
3.2.7.2 Immunomodulatory activities 
 
F. lucidum and C. sinensis have shown immunomodulatory properties in the literature 
(Li et al., 2003, Nie et al., 2013, Shashidhar et al., 2013, Zhang and Zhang, 2011, Zhao 
et al., 2010). It is therefore, interesting to evaluate immunomodulatory properties of 
polysaccharides extracted from these mushrooms. 
 
3.2.7.2.1 Cell Culturing (RAW 264.7) 
 
A culture medium containing 45 ml DMEM (Dulbecco's Modified Eagle Medium), 5 
ml of 10% FBS and 500µl of penicillin and streptomycin was prepared and stored at 
4°C for later use. Macrophages (RAW 264.7) were then added to complete media and 
incubated at 37°C in 5% CO2 in an incubator and over served daily until reach 85% 
confluency. Dilution of cells was done with medium to achieve density 2×105 cells/ml. 
After achieving cell density macrophages were ready for analysis. 
 
3.2.7.2.2 Toxicity assay 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used 
to analyse the viability of (RAW 264.7) macrophage cells (Thambiraj et al., 2015, 
Zhang, 2017). The macrophage cells (RAW 264.7) were cultured as described in the 
above section. 200µl of media containing cells with a density 2×105 cells/ml was 
transferred to 96 well plates and incubated for 48 hours. After the incubation, old media 
was discarded and 180µl of fresh complete media was added to the plate and then 
treated with 20µl of mushroom polysaccharides and incubated at 37⁰C for 18 hours. 
After incubation, the supernatant was discarded and 100 μl of MTT solution (prepared 
in 0.2 mg/ml in complete DMEM) added to each well and incubated for 4 hours at
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37⁰C. The supernatant was removed and 100 μl DMSO was added to each well. The 
absorbance was measured using UV spectrophotometer (SpectrostarNano BMG 
LABTECH) at 595 nm. 
 
𝐀𝐛𝐬𝐨𝐫𝐛𝐚𝐧𝐜𝐞 𝐨𝐟 𝐬𝐚𝐦𝐩𝐥𝐞 
𝐂𝐞𝐥𝐥 𝐯𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 % = 




A positive control is macrophages cells treated with only complete DMEM medium 
(no sample) 
3.2.7.2.3 Assay for the measurement of IL-6 production 
 
10ml of complete media (DMEM) was added to mouse macrophages (RAW 264.7) 
and incubated for 4 days at 37°C in 5% CO2 in an incubator and observed daily until 
85% confluency. 200µl of media containing cells with a density 2×105 cells/ml was 
transferred to 96 well plates and incubated for 48 hours (Thambiraj et al., 2015, Zhang, 
2017). After the incubation, old media was discarded and 180µl of fresh complete 
media was added to the plate and then treated with 20µl of mushroom polysaccharides 
and incubated at 37⁰C for 18 hours. After incubation, the supernatant was transferred 
to IL-6 antibody coated ELISA plates. The measurement of IL-6 production was 
measured using the manufacturer’s manual. The standard curve equation obtained 
from IL-6 standard was used to calculate IL-6 production capacity of polysaccharide 
samples. 
 
3.2.7.2.4 Assay for the measurement of TNF- α production 
 
10ml of complete media (DMEM) was added to mouse macrophages (RAW 264.7) 
and incubated for 4 days at 37°C in 5% CO2 in an incubator and observed daily until 
85% confluence. 200µl of media containing cells with a density 2×105 cells/ml was 
transferred to 96 well plates and incubated for 48 hours (Thambiraj et al., 2015, Zhang, 
66  
2017). After the incubation, old media was discarded and 180µl of fresh complete 
media was added to the plate and then treated with 20µl of mushroom polysaccharides 
and incubated at 37⁰C for 18 hours. After incubation, the supernatant was transferred 
to TNF-α antibody coated ELISA plates. The measurement of TNF-α production was 
measured using the manufacturer’s manual. The standard curve equation obtained 
from IL-6 standard was used to calculate TNF-α production capacity of polysaccharide 
samples. 
 
3.2.7.3 Anticancer activities 
 
Cytotoxicity of polysaccharides against cancer cell lines can be measured using 
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay (Ravipati et al., 2013). To 
calculate cytotoxicity activity of polysaccharides, PC3 cells (human prostate cancer, 
ATCC Cat. No. ATCC® CRL-1435TM), were cultured in RPMI 1640 (Life 
Technologies, Australia) containing 10% foetal bovine serum (FBS), L-glutamine and 
1% antibiotics (penicillin/streptomycin). Cells were incubated at 37°C at 5% CO2 to 
reach 80% confluency (Zaman et al., 2019). 200µl of media containing cells with a 
density 2×105 cells/ml was transferred to 96 well plates and incubated for 48 hours. 
After 24 hrs incubated cells were treated with 10µl of each polysaccharide samples at 
different concentrations (4µM, 2µM, 1µM, 0.5µM) to the media already present in 96 
well plate and incubated for 24 hrs. After incubation, the supernatant was removed 
from the wells and 100µl of Methylthiazolyldiphenyl-tetrazolium bromide (MTT) was 
applied to treated cells and incubated again for 2 hrs at 37°C and 5% CO2. After 
incubation, 100µl of DMSO was added to solubilise dark blue formazan insoluble 
crystals. The absorption was measured at 595 nm in a spectrofluorometer. The % cell 
death was calculated by using the equation given below. 
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(𝐀𝐜𝐨𝐧𝐭𝐫𝐨𝐥  − 𝐀𝐬𝐚𝐦𝐩𝐥𝐞 ) 






Where Acontrol is PC3 cell lines treated with RPMI 1640 medium without any sample 
and Asample is the absorbance of cell lines treated with samples. 
 
3.2.7.4 Prebiotic activities 
 
Polysaccharides can act as a carbohydrate source for probiotic bacteria such as 
Bifidobacteria (B. lactis DR10 and B. animalis BB-12) and Lactobacillus (L. 
rhamnosus DR20 and L. acidophilus LAFTI L10) (Singdevsachan et al., 2016). So, 
mushroom polysaccharides were analysed for their ability to act as a a primary 
carbohydrate source of probiotic bacteria listed above. The cultures were maintained 
on Reinforced Clostridia agar and the medium for analysing prebiotic characteristics 
was based on Reinforced Clostridial media without carbohydrate (consisting of 3 g of 
yeast extract, 10 g of peptone, 10 g of Lab-Lemco powder, 0.5 g of cysteine 
hydrochloride, 5 g of sodium chloride, 0.5% polysaccharide fractions and Inulin as a 
positive control in 1L deionised water). The media was autoclaved at 121 °C. The 
media was then transferred in 5 mL lots into each autoclaved test tubes. The initial pH 
was measured. The final pH was measured after 72 hrs. Decrease in pH (carbohydrate 
fermentation) indicated the bacterial growth (Thambiraj et al., 2018). 
3.2.8 Statistical analysis 
Data were analysed in triplicate and mean ± SD was determined. Statistical 
calculations were performed using Origin Pro 8.5 and Excel 2016. The data were 
statistically significant if p < 0.05. 
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Chapter – 4 
 
Antioxidant and immunomodulatory 






Medicinal mushrooms have been known for their importance as a source of novel 
therapeutic agents and they form potential leads for the discovery of new 
pharmaceuticals (Friedman, 2016, Girometta, 2019, Guo et al., 2009, Huang et al., 
2018). Medicinal mushrooms have contributed significantly to the development of 
important therapeutics including immune-enhancing and anticancer drugs and hence it 
is useful to examine their remedial value using contemporary scientific tools (Shah et 
al., 2013). Several medicinal mushrooms have been used traditionally to treat different 
types of cancers in Asian countries as well as contemporary western world (Abotaleb 
et al., 2018, Daba and Ezeronye, 2003, Nie et al., 2013, Shah et al., 2013, Zhang et al., 
2018a, Zhang et al., 2007). However, the majority of these are yet to be investigated in 
detail for the discovery of therapeutic agents such as polysaccharides. 
The literature on some of these molecules and their anticancer potentials are briefly 
discussed below. The bioactivities of mushrooms have been confirmed by extensive 
studies (Alam et al., 2013, Bao et al., 2001, Cao and Lin, 2004, Chen et al., 2013, Cui 
and Chisti, 2003, Daba and Ezeronye, 2003, Jeong et al., 2004). Several medicinal 
mushrooms were identified and used to treat cancer in traditional Chinese medicine 
(TCM) for many centuries (Alam et al., 2013, Bao et al., 2001, Cao and Lin, 2004). For 
instance, Coriolus versicolor is one such mushroom that has been well investigated and 
is currently used in China and Japan in combination with chemotherapy (Cui and 
Chisti, 2003, Jeong et al., 2004). Several antitumor polysaccharides have been 
extracted from a variety of medicinal mushrooms (Cui and Chisti, 2003, Friedman, 
2016, Jeong et al., 2004, Vetvicka and Vetvickova, 2012, Zhang and Reddy, 2018, 
Zhang et al., 2014, Zhang et al., 2007). For instance, β-glucans isolated from medicinal 
mushroom (such as Coriolus versicolor, Schizophyllum commune), have proven to 
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possess pharmacological effects such as immunomodulatory, anticancer, anti- 
inflammatory and antioxidant activities (Cui and Chisti, 2003, Jeong et al., 2004, 
Komatsu et al., 1969, Smirnou et al., 2017, Zhang et al., 2013). In particular, several 
polysaccharides and polysaccharoproteins have been isolated from medicinal 
mushrooms and some of them are in clinical use for anticancer therapy (Cui and Chisti, 
2003, Friedman, 2016, Jeong et al., 2004, Vetvicka and Vetvickova, 2012, Zhang and 
Reddy, 2018, Zhang et al., 2014, Zhang et al., 2007). For example, lentinan derived 
from Lentinula edodes (Ina et al., 2013, Wang et al., 2017, Zhang et al., 2011), 
polysaccharide krestin (PSK) derived from Coriolus versicolor (Cui and Chisti, 2003, 
Friedman, 2016, Jeong et al., 2004, Torisu et al., 1990, Zhang et al., 2018b, Zhang et 
al., 2007); polysaccharopeptide (PSP) isolated from Coriolus versicolor (Cui and 
Chisti, 2003, Friedman, 2016, Jeong et al., 2004, Torisu et al., 1990, Zhang et al., 
2018b, Zhang et al., 2007); and Schizophyllan from Schizophyllum commune 
(Komatsu et al., 1969, Smirnou et al., 2017, Zhang et al., 2013) are some of the 
important immune-enhancing and anticancer polysaccharides. As part of the ongoing 
research program in our laboratory, a few important traditional Chinese medicinal 
mushrooms (Amauroderma rugosum, Artemisia annua, and Lobelia chinensis) were 
studied for their immune-enhancing and anticancer properties (Zhang, 2017). 
Based on these facts, traditionally known medicinal mushrooms (Ganoderma lucidum 
and Cordyceps sinensis) were chosen for this project and their polysaccharides were 
investigated for antioxidant, immunomodulatory, prebiotic and anticancer properties. 
This chapter presents the results of their antioxidant and immunomodulatory 
properties. The literature on these mushrooms is briefly reviewed and presented in 
Chapter 2 (section 2.9). 
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This study involves hot water extraction of polysaccharides, deproteination and 
fractionation of polysaccharides employing size exclusion chromatography and then 
study their bioactivities. The objectives of this chapter are to isolate water-soluble 
polysaccharides from hot water extracts of both mushrooms and to determine their 
antioxidant and immunomodulatory properties. 
In this study, antioxidant activities of the selected herbal extracts were evaluated by 
ABTS●+ scavenging (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid), OH 
radical scavenging and Iron chelating assays (Alam et al., 2013, Li et al., 2011, 
Umamaheswari and Chatterjee, 2007). Immunomodulatory activities of water-soluble 
polysaccharides were evaluated by measuring their ability to activate macrophages and 
produce cytokines such as IL-6 and TNF-α (Zhang and Zhang, 2011). The toxicity of 
these water-soluble polysaccharides was determined by employing MTT assay (Zhang 
and Zhang, 2011). 
4.2 Methodology 
4.2.1 Extraction of crude polysaccharides from traditional medicinal mushrooms 
Briefly, 20 gm of a powdered sample of each mushroom was dissolved in 100ml 
distilled water and autoclaved at 121°C for an hour (Zhang et al., 2012). The detailed 
experimental procedure is described in Chapter 3 (section 3.2.1). The freeze-dried 
polysaccharide samples obtained from the extraction were then stored at -30°C until 
further examination. 
4.2.2 Analysis of chemical composition 
 
4.2.2.1 Total sugar analysis 
 
Phenol sulphuric assay with slight modifications (DuBois et al., 1956) was employed to analyse 




4.2.2.2 Protein analysis 
 
Lowry assay with slight modification was implemented to analyse the protein content 
of polysaccharides (Lowry et al., 1951, Zhang et al., 2012). After following the detailed 
procedure outlined in chapter 3 (section 3.2.2). The reaction mixture was incubated for 
30 minutes and the absorbance was measured at 750 nm in a spectrophotometer. 
4.2.3 Deproteination of polysaccharide samples 
 
Sevag method was employed to remove proteins from polysaccharides (Staub, 1965). 
A Sevag reagent was prepared by mixing n-butanol and chloroform in 1:4 vol|vol ratio 
(Seedevi et al., 2013). Details of this procedure are outlined in Chapter 3 (section 
3.2.3). The whole procedure was repeated until the whole protein was completely 
removed. Polysaccharide samples were then precipitated in ethanol and dissolved in 
water and freeze-dried for later use (Seedevi et al., 2013, Zhang, 2017). 
4.2.4 Purification of polysaccharides using Size Exclusion Chromatography 
4.2.4.1 Determination of molecular weights of polysaccharide fractions  
Sepharose CL-6B gel was used to home pack a large (100 cm x 5 cm) column. Details 
of column packing and separation method are described in chapter 3 (section 3.2.4). 
Standard dextrans with different molecular weights were used for building a standard 
curve. A standard curve with straight-line equation of y = -0.2324x + 1.5483, R² = 
0.9024 was obtained using the sugar profile (Fig 4.4). The same procedure was 
repeated for the separation of mushroom polysaccharides with a concentration 
20mg/ml and sugar profile was determined using the phenol-sulphuric acid method. 
The relevant fractions were collected and freeze-dried. The standard curve plot was 
used to estimate molecular weights of the purified polysaccharide fractions. The details 
of this assay are given in chapter 3 (section 3.2.4). 
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4.2.5 Evaluation of biological activities of mushroom polysaccharides 
 
4.2.5.1 Antioxidant activities 
 
4.2.5.1.1 ABTS (2,2′-Azinobis-(3-Ethylbenzthiazolin-6-Sulfonic Acid) radical 
scavenging assay 
The procedure to perform this assay is described in chapter 3 (section 3.2.7.1.1). A 
standard straight-line equation Y = -0.0022x+0.5839, R2 = 0.9944 was obtained for the 
scavenging activities of ascorbic acid and was used for calculating the scavenging 
activities in terms of ascorbate equivalence. All measurements were performed in 
triplicate to minimise the error. 
4.2.5.1.2 OH˙ scavenging assay 
 
The procedure to perform this assay is described in chapter 3 (section 3.2.7.1.2). 
 
4.2.5.1.3 Fe2+ chelating activity 
 
The chelating activities of polysaccharides were estimated by the method of Decker and 
Welch with slight modifications (Decker and Welch, 1990, Wang et al., 2008, Zhang, 
2017). Ethylenediaminetetraacetic acid (EDTA) was used as a positive control. Details 
are given in chapter 3 (section 3.2.7.1.3). 
4.2.5.2 Immunomodulatory activities 
 
4.2.5.2.1 Cell Culturing (RAW 264.7) 
 
A culture medium containing 45 ml DMEM, 5 ml of 10% FBS and 500µl of 
penicillin/streptomycin was prepared. Macrophages (RAW 264.7) were cultured to 
achieve a cell density of density 2×105 cells/ml. After achieving the confluence, the cells 




4.2.5.2.2 Toxicity assay 
 
Viability of macrophage cells (RAW 264.7) was measured by employing MTT assay 
(Zhang, 2017). Details are given in chapter 3 (section 3.2.7.2.2) 
4.2.5.2.3 Assay for the measurement of IL-6 production 
 
A complete media (DMEM) was used for dilution of cells to achieve density of 2x105 
cells/ml. Then treated with polysaccharide samples incubated overnight. ELISA kit was 
used to measure the production of IL-6 by following the procedure provided in the 
manufacturer’s manual. The standard curve equation y = 0.0024x + 0.1514, R² = 0.9781 
obtained with IL-6 standard was used to calculate the concentration of IL-6 produced by. 
Full details of the procedure are given in chapter 3 (section 3.2.7.2.3) 
4.2.5.2.4 Assay for the measurement of TNF- α production 
 
Cells were diluted with the medium to achieve a density of 2x105 cells/ml. Then treated 
with polysaccharide samples incubated overnight. ELISA kit was used to measure the 
production of TNF-α by following the procedure provided in the manufacturer’s manual. 
The standard curve equation y = 0.0008x + 0.1194, R² = 0.9873 obtained with TNF-α 
standard was used to calculate the concentration of TNF-α produced by the 
polysaccharide extracts. Details of the procedure are given in chapter 3 (section 
3.2.7.2.4) 
4.3 Results and discussion 
 
4.3.1 Extraction yield of polysaccharides 
 
Mushroom polysaccharides were extracted using hot water extraction method (Chang 
and Lu, 2004, Yang et al., 2013). The extraction yield (g/Kg) of polysaccharides is given 
in table 4.1. The extraction yield is maximum for C. sinensis followed by G. lucidum. 
The lesser yield of G. lucidum spores is reasonable because spores are a part  of the
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 mushroom body. The difference in yield of G. lucidum and C. sinensis could be due to 
the harder cell wall structure of former mushroom and it may contain smaller quantities 
of water-soluble polysaccharides. 
Table 4.1: Hot water extraction yield (g/Kg) of crude mushroom polysaccharides 
 
 
Cordyceps sinensis 154.31 




4.3.2 Deproteination of polysaccharides 
 
Crude polysaccharides were deproteinated using Sevag method, the yield (g/100gm) of 
deproteinated polysaccharides is presented in table 4.2. Sevag method was repeated 5 to 
6 times to remove the maximum possible free proteins from crude polysaccharides. The 
picture (Fig 4.2) below shows the polysaccharides dissolved in water before and after 
deproteination. Deproteination resulted in a clear polysaccharide solution indicating that 
all the particulates including the marc and fibre are removed. The results are given in 
Table 4.2, clearly shows that C. sinensis has maximum polysaccharide content followed 
by G. lucidum and G. lucidum spores have the least amount of polysaccharides. 
Table 4.2: Deproteinated polysaccharide yield (g/100gm) 
 
C. sinensis 34.45 
G. lucidum 40.73 
 
yield g/Kg 









Crude PS sample in water Deproteinated PS sample in water  
Fig 4.1: Polysaccharide sample dissolved in water before and after deproteination 
4.3.3 Chemical composition of crude polysaccharides 
The total sugar content of polysaccharides extracted from the selected mushrooms was 
measured using the phenol-sulphuric acid method (DuBois et al., 1956) and the results 
are presented in table 4.3. It is clear that most polysaccharides contained a significant 
quantity of total sugar content. 
Table 4.3: % Carbohydrate and protein content of crude polysaccharides 
 




C. sinensis 63.43% 36.56% 
G. lucidum 66.94% 33.05% 
4.3.4  Chemical composition of deproteinated polysaccharides 
 
The total sugar content of deproteinated polysaccharides of crude polysaccharides was 
measured using Phenol-sulphuric assay (DuBois et al., 1956) and the results are given 
in Table 4.4. It is clear that most polysaccharides contained a significant quantity of 







Table 4.4: % Carbohydrate and protein content of deproteinated Polysaccharides 




C. sinensis 83.39% 16.41% 
G. lucidum 86.34% 13.65% 
 
4.3.5 Fractionation and purification of polysaccharides using size exclusion 
Chromatography 
 
Polysaccharides extracted from G. lucidum and C. sinensis were fractionated by using 
Sepharose CL-6B size-exclusion chromatography. Four fractions were collected from 
G. lucidum and two fractions were collected from C. sinensis on the basis of their 
carbohydrate elution profiles obtained by phenol-sulphuric acid assay (DuBois et al., 
1956, Brummer and Cui, 2005). The polysaccharide fractions extracted from G. 
lucidum were named as GLP-1 (M.wt: 2965kDa), GLP-2 (M. wt: 925kDa), GLP-3 (M. 
wt: 186kDa) and GLP-4 (M. wt: 1.3kDa) (Fig. 4.2). The polysaccharide fractions 
extracted from C. sinensis were named as CSP-1 and CSP-2 (Fig. 4.3). The standard 
curve was plotted against Log10 molecular weight (Da) and Kav (Fig 4.4). Kav was 
calculated by using the following equation. 






Where Vo is void volume, Vt is total volume, Ve is elution volume of each sample. 
 
This standard curve equation y = -0.2324x + 1.5483, R² = 0.9024 (Fig 4.4) was used 
to calculate molecular weights of polysaccharide fractions. The molecular weights of 












G. lucidum GLP-1 2965 
 GLP-2 925 
 GLP-3 186 
 GLP-4 1.3 
C. sinensis CSP-1 1237 















































































































































Fig 4.4: Calibration curve obtained by using standard dextran series. 
 
4.3.6 Bioactivities of polysaccharides 
 
4.3.6.1 Antioxidant activities of polysaccharides 
 
Reactive oxygen species (ROS) are formed in the body during metabolic processes and 
by environmental factors (Jomova and Valko, 2011). Prolonged presence of these 
reactive oxygen species in the body can damage DNA and proteins hence cause 
oxidative stress which has the potential to cause life-threatening illnesses. Free Fe2+ in 
the body increases the chance of DNA destruction (Jomova and Valko, 2011). 
Antioxidant molecules are therefore extremely useful because of their ability to 
eliminate free radicals that can results in DNA destruction and consequent health 
issues. With a view to analyse antioxidant potentials of these mushroom 
polysaccharides, their abilities to scavenge ABTS●+ And OH● free radicals and to 
chelate with Fe2+ have been tested (Alam et al., 2013, Chen et al., 2017, Ferreira et al., 
2015, Jia et al., 2009, Kang et al., 2019, Ma et al., 2012). These results are presented 
below. 
Log10 (Molecular weight) (Da) 











y = -0.2324x + 1.5483 










4.3.6.1.1 ABTS●+ scavenging activity 
 
ABTS●+ scavenging activity of dextrans – a potential negative control 
Negative controls are generally used for analysing biological activities. However, until 
now there is no known polysaccharide in the literature that can be used as a negative 
control. With a view to develop a suitable negative control for radical scavenging 
activity, two dextran samples of different molecular weights 40 kDa and 400kDa were 
studied in this project. The results are presented below in Fig 4.5. The concentration-
dependent scavenging activities for dextran samples of two different molecular masses 
clearly indicate that their activities are independent of concentration. These results 
demonstrate that the activities exhibited by both dextran samples at highest 
concentration studied are very similar to the activities shown by the samples with the 
lowest concentration; which in turn was very similar to the activity shown by the blank 
(baseline activity). Hence, it is concluded that the Dextran samples with various 
molecular masses do not display any radical scavenging activities. It is therefore 
concluded that the Dextran samples can be used as a negative control for radical 















Fig 4.5: %ABTS•+ scavenging activity dextrans with a different molecular weight (400kDa, 40kDa) 
Concentration of Dextrans (µg/ml) 
1000 800 600 400 200 





































ABTS•+ scavenging activity of G. lucidum polysaccharides (GLPs) 
 
ABTS•+ scavenging activities of fractionated GLPs in a dose-dependent manner are 
presented in Fig 4.6(b). Out of the four fractions, GLP-2 showed highest ABTS•+ 
scavenging activity followed by GLP-1, GLP-3 and least activity is shown by GLP-4. 
The literature demonstrate that, high molecular weights are favourable for bioactivities 
of polysaccharides (Jeong et al., 2012, Zhang et al., 2014) so, GLP-1 (2964kDa) and 
GLP-2 (925kDa) showing higher activities than GLP-3 (186kDa) and GLP-4 (1.3kDa) 
is consistent. FTIR studies (Chapter -5, section 5.3.3) shows that GLP-1 and GLP-2 
contain β- glycosidic linkage with furanose ring structures. It should be noted that, 
GLP-1 is less active than GLP-2 in spite of having high molecular weight. This may be 
explained on the basis of branched structure (degree of branching). The literature 
demonstrates that polysaccharides with the branched structure are likely to have higher 
activity (Jeong et al., 2012, Zhang et al., 2014). GLP-3 and GLP-4 both contain 
pyranose rings with β- glycosidic linkage and GLP-4 additionally exhibits α-glycosidic 
linkage. Presence of additional α-glycosidic linkage could be the reason for its weaker 
radical scavenging activity. 
ABTS•+ scavenging activity of C. sinensis polysaccharides (CSPs) 
 
ABTS•+ scavenging potentials of CSPs are presented in Fig 4.7. CSP polysaccharides 
exhibited significant scavenging activity against ABTS•+ radical in a dose-dependent 
manner (Fig 4.7). Crude CSP showed the best ABTS•+ radical scavenging ability which 
is significantly greater than deproteinated CSP (De CSP). 
ABTS•+ scavenging activities of fractionated CSPs: ABTS•+ scavenging ability of 
CSP-1 is presented in Fig 4.7. CSP-2 fraction yielded only a small quantity in SEC 







































shown significant activity towards ABTS•+ scavenging. In spite of having a similar 
average molecular weight (as that of GLP-2), CSP-1 has shown less activity than the 
activity shown by GLP-2 polysaccharides. This can be explained with FTIR spectral 
characteristics of these two polysaccharides (Chapter 5), CSP-1 contains a pyranose 
ring with α-, and β- glycosidic linkages whereas GLP-2 contains a furanose ring with 
only β- glycosidic linkages. As discussed earlier, α- glycosidic linkages can lower the 
activity of polysaccharides. ABTS•+ scavenging activity of CSPs in terms of ascorbate 
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Fig 4.6: %ABTS•+ scavenging activity GLPs; (a) % ABTS•+ radical scavenging activity 
of Crude GLP & De GLP; (b) % ABTS•+ radical scavenging activity of GLP-1, 




Table 4.5: ABTS•+ scavenging activity of GLPs & CSPs expressed in terms of the activity of 









1 Crude GLP 155.71±3.19 
2 De GLP 145.41±3.18 
3 GLP-1 90.26±3.03 
4 GLP-2 140.41±1.20 
5 GLP-3 63.89±1.72 
6 GLP-4 8.14±0.45 
7 Crude CSP 83.44±2.58 
8 De CSP 53.44±0.95 















Fig 4.7: %ABTS•+ scavenging activity CSPs (n = 3, p < 0.03). 
 
Results presented in this section also indicate that the crude CSPs displayed higher 
radical scavenging activity than deproteinated CSPs against ABTS•+ radical. This may 
be because of the fact that the protein component of CS biopolymer may be more active 
than the polysaccharide component. Similar results were observed for radical 
scavenging activities of GLPs. 
4.3.6.1.2 OH• Scavenging activity of polysaccharides 
OH• is a biologically relevant reactive oxygen species and is formed during metabolic 
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2004). Such an undesirable process can be prevented using radical scavenging agents 
(antioxidants). Polysaccharides are well known antioxidants; it is, therefore, 
interesting to know OH• scavenging capacity of mushroom polysaccharides. 
OH• Scavenging activity of G. lucidum polysaccharides (GLPs) 
 
OH• scavenging activities GLPs polysaccharides have been determined in a dose- 
dependent manner and are presented in Fig 4.8(b). The results presented for OH• 
scavenging activity are consistent with results obtained from ABTS•+ scavenging 
assay. GLP-2 showed highest OH• scavenging activity followed by GLP-1, GLP-3 and 
least activity is shown by GLP-4. Larger molecular weights are favourable for 
antioxidant activities of polysaccharides (Jeong et al., 2012, Zhang et al., 2014). FTIR 
studies (chapter 5 section 5.3.3) provides similar structural interpretation as was done 
for the scavenging activities against ABTS•+ radicals (section 4.3.1.3). Hydroxyl 
radical scavenging potentials of the crude, deproteinated and GLPs are given in Fig 























































Fig 4.8: OH• scavenging activity (a) OH• scavenging activity of Crude GLP & De GLP; (b) OH• 
scavenging activity of GLP-1, GLP-2, GLP-3 and GLP-4; (c) OH• scavenging activity of 
CSP-1, Crude CSP and De CSP (n = 3, p < 0.03). 
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OH• Scavenging activity of C. sinensis polysaccharides (CSPs) 
 
Hydroxyl radical scavenging potentials of the CSP-1 in a dose-dependent manner are 
given in Fig 4.8(c). CSP-1 has shown significant activity towards OH• scavenging. 
These activities are comparable to those of GLPs. 
Results presented in this section indicate that the crude CSPs displayed higher radical 
scavenging activity than deproteinated CSPs against OH• radicals. This may be due to 
the fact that the protein component of CS biopolymer may be more active than the 
polysaccharide component. Similar results were observed for radical scavenging 
activities of GLPs. 
4.3.6.1.3 Fe2+ chelating activity of Polysaccharides 
 
Fe2+ chelating activities of GLPs 
Fe2+ chelating activities of fractionated GLPs polysaccharides in a dose-dependent 
manner are presented in Fig 4.9(b). The Fe2+ chelating capacity of the polysaccharide 
extracts was examined by spectrophotometric method (section 5.3.3). The absorbance 
of the orange coloured complex formed in the reaction decreases as the concentration 
of the polysaccharide- Fe2+ complex increases. These results demonstrate that, GLP-3 
and GLP-4 have shown higher activity than GLP-1 and GLP-2 (Fig 4.9) (this 
observation contrasts with radical scavenging activities) (Fig 4.9). FTIR spectra of 
GLP-3, GLP-4 shows that they both contain pyranose rings. Previous studies reveal that 
galactose and glucose (pyranose rings) are most suitable candidates for the chelating 
ability of these polysaccharides (Jeong et al., 2012, Zhang et al., 2014) Whereas GLP-
1 & GLP-2 has furanose structure, which may be responsible for significantly lower 
activity. 
Fe2+ chelating activity of CSPs 
Fe2+ chelating activities of fractionated CSP-1 polysaccharides in a dose-dependent  
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manner are presented in Fig 4.9(c). Fe2+ chelating activities exhibited by CSP-1 
polysaccharide has shown significant Fe2+ chelating activity. The activity shown by 
CSP-1 at the highest concentration (1000µg/ml) is 60%. CSP-1 comprises a pyranose 
ring with α- & β- glycosidic linkages. As discussed earlier pyranose ring favours Fe2+ 
chelation (Jeong et al., 2012, Zhang et al., 2014). 
Results presented in this section indicate that the crude CSPs displayed Fe2+ chelation 
activity than deproteinated CSPs and GLPs. This may be due to the fact that; the 
protein component of biopolymer may be more active than the polysaccharide 






















































Fig 4.9: Ferrous chelating activity; (a) Ferrous chelating activity of Cr GLP & De GLP; 
(b) Ferrous chelating activity of GLP-1, GLP-2, GLP-3 & GLP-4; (c) Ferrous 
chelating activity of Cr CSP, De CSP & CSP-1 (expressed in terms of the chelating 
activity of EDTA at 50µg/ml taken as 100%) (n = 3, p < 0.03). 
 
 
Concentration of Polysaccharides (µg/ml) 































1000 500 250 125 62.5 
Concentration of polysaccharides (µg/ml) 
62.5 125 250 500 








































































4.3.6.2 Immunomodulatory activities of polysaccharides 
 
Immunostimulatory activities of polysaccharides isolated from medicinal mushrooms 
were measured in terms of their capacity to activate mouse macrophages (RAW 264.7) 
by producing cytokines such as TNF-α and IL-6. Mouse macrophages (RAW 264.7) 
were treated with polysaccharide samples and the results demonstrated a dose- 
dependent increase in the production of TNF-α and IL-6 cytokines. The results are 
presented in Figures 4.10 (a)&(b) and 4.11(a)&(b). 
4.3.6.2.1 TNF-α Production of polysaccharides 
TNF-α production of GLPs 
The results of TNF- α production of GLP-1 GLP-2 & GLP-3 in a dose-dependent 
manner is presented in Fig 4.10 (a)&(b). GLP-4 fraction yielded in a very small amount 
during SEC purification and was not enough to undertake further biological studies. 
The results of TNF-α production clearly indicate that all the polysaccharide fractions 
isolated from G. lucidum have induced activation of macrophages and lead to 
significant production of TNF-α. All GLP fractions have displayed significant 
immunostimulatory activities with respect to the production of TNF-α in a 
concentration-dependent manner in the range of 62.5 to 1000μg/mL (Figure 4.10 (a)). 
GLP-1 has exhibited excellent immunostimulatory activities (Figure 4.10 (b)) as 
evidenced by the observation that there is more than 15-fold increase in the production 
of TNF-α (at 1000μg/mL) when compared with untreated macrophages (control). It 
can also be seen from the results that GLP-3 has exhibited highest activity as 
demonstrated by the fact that there is more than 16-fold increase in the production of 
TNF-α (at 1000μg/mL) when compared with untreated macrophages (control). 
Whereas GLP-2 has exhibited about 10-fold increase in the production of TNF-α (at 




































and structure obtained from FTIR spectral studies (Chapter 5). GLP-1 (2964kDa) and 
GLP-2 (925kDa) have furanose ring with β-glycosidic linkages. Whereas GLP-3 is 
low molecular weight polysaccharides (186kDa) with pyranose ring and β-glycosidic 
linkage. From literature, it is known that polysaccharides with high molecular weight 
and pyranose ring structures are favourable for immunomodulatory activities (Zhang 
et al., 2014). Production of TNF-α cytokines presented in fig 4.10 (a)&(b) is consistent 
with their structures. GLP-1 and GLP-3 displayed highly significant 
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Fig 4.10: Immunostimulatory activities of GLP-1, GLP-2 and GLP-3; (a) TNF-α production (100 
ng of LPS that produced 623pg/mL of TNF-α was considered as positive control); control 
is TNF- α produced by untreated macrophages (n = 3, p < 0.05); (b) %TNF-α production 
by GLP-1, GLP-2 and GLP-3. 
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TNF-α production of CSPs 
The immunomodulatory activity of CSP-1 with respect to TNF-α production in a dose- 
dependent manner is presented in Fig 4.11 (a)&(b). These results clearly indicate that 
CSP-1 has significantly induced activation of macrophages and lead to production of 
large quantities of TNF-α. CSP-1 has exhibited excellent immunostimulatory activity 
(Figure 4.11(b)) as evidenced by the observation that there is about 10-fold increase in 
the production of TNF-α at a maximum concentration as compared to untreated 
macrophages (control). CSP-1 is a polysaccharide containing pyranose ring structure 
with α and β-glycosidic linkages. These observations are consistent with the 
immunomodulatory activities of C. sinensis polysaccharides reported in the literature 




































Fig 4.11: Immunostimulatory activities of CSP-1; (a) TNF-α production (100 ng of LPS that 
produced 623pg/mL of TNF-α was considered as positive control); control is TNF- α 
produced by untreated macrophages (n = 3, p < 0.05); (b) %TNF-α production by CSP-1. 
 
TNF-α Production of A. rugosum 
A. rugosum is a medicinal mushroom studied by previous co-workers in our laboratory. 
In previous studies, ARPs have displayed highly significant immunostimulatory 
activities (Zhang, 2017) and significant quantity of ARP-1 was available in Author’s 
laboratory. Therefore, ARP-1 was used as a known standard to compare the results of 
immunomodulatory activities of G. lucidum and C. sinensis polysaccharides. 
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Fig 4.12: Immunostimulatory activities of ARP-1with respect to TNF-α production (100 ng of LPS 
that produced 623pg/mL of TNF-α was considered as positive control); control is TNF- α 
produced by untreated macrophages (n = 3, p < 0.05) 
 
The immunomodulatory activity of ARP-1 with respect to TNF-α production in a dose- 
dependent manner is presented in Fig 4.12 (a) and (b). These results clearly indicate that 
ARP-1 has displayed excellent immune stimulatory activities with respect to the 
production of TNF-α. ARP-1 has exhibited about 60-fold increase in the production of 
TNF-α (at 1000μg/mL). 
As can be seen from the results presented in Figs 4.10 to 4.12, ARP-1 has displayed 
superior immunostimulatory activity than GLPs and CSPs. ARP-1 has exhibited highly 
effective immunostimulatory activity (Figure 4.12(b)) as evidenced by the observation 
that there is more than 16-fold increase in the production of TNF-α at the concentration 
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of 500µg/mL as compared to untreated macrophages (control). 
4.3.6.2.2 IL-6 Production of polysaccharides  
IL-6 production of GLPs  
The results presented in Fig 4.13 (a) and (b) clearly indicate that the polysaccharide 
fractions isolated from G. lucidum have induced significant activation of macrophages 
and lead to the production of large quantities of IL-6. GLP-1 has displayed high 
immunostimulatory activity with respect to the production of IL-6 in a concentration- 
dependent manner in the range of 62.5 to 1000μg/mL (Figure 4.13(a)). GLP-1 has 
exhibited excellent immunostimulatory activity (Figure 4.13(b)) as evidenced by the 
observation that there is around 40-fold increase in the production of IL-6 (at 
1000μg/mL) when compared with untreated macrophages (control). It can also be seen 
from the results that GLP-3 has exhibited highly significant activity as evidenced by the 
fact that there is more than 50-fold increase in the production of IL-6 (at 1000μg/mL) 
when compared with untreated macrophages (control). Whereas GLP-2 has exhibited an 
only 30-fold increase in the production of IL-6 (at 1000μg/mL). These findings 
demonstrate that GLP-1 and GLP-3 are the most active immunostimulatory agents with 
respect to IL-6 production and are promising candidates for the development of immune 
enhancing formulations suitable for immune-chemotherapy as well as to enhance the 




































Fig 4.13: Immunostimulatory activities of GLP-1, GLP-2 and GLP-3; (a) IL-6 production (100 ng 
of LPS that produced 491pg/mL of IL-6 was considered as positive control); control is IL-6 
produced by untreated macrophages (n = 3, p < 0.05); (b) %IL-6 production by GLP-1, 
GLP-2 and GLP-3. 
 
IL-6 Production of C. sinensis 
The results presented in Fig 4.14 (a) and (b) clearly indicate that the polysaccharides 
isolated from C. sinensis have induced activation of macrophages and lead to 
significant production of IL-6. CSP-1 has displayed high immunostimulatory activities 
with respect to the production of IL-6 in a concentration dependent manner in the range 
of 62.5 to 1000μg/mL (Fig 4.14 (a)). CSP-1 has exhibited excellent 
immunostimulatory activity (Fig 4.14 (b)) as evidenced by the observation that there 
is more than 40-fold increase in the production of IL-6 (at 1000μg/mL) when compared 
with untreated macrophages (control).
Concentration of polysaccharides (µg/ml) 



















Concentration of Polysaccharide fractions (µg/ml) 









































































Fig 4.14: Immunostimulatory activities of CSP-1; (a) IL-6 production (100 ng of LPS that produced 
623pg/mL of IL-6 was considered as positive control); control is IL-6 produced by untreated 
macrophages (n = 3, p < 0.05); (b) %IL-6 production by CSP-1. 
 
IL-6 Production of A. rugosum 
The immunomodulatory activity of ARP-1 with respect to IL-6 production in a dose- 
dependent manner is presented in Fig 4.15 (a) and (b). These results clearly indicate 
that ARP-1 has displayed excellent immunostimulatory activities with respect to the 
production of IL-6. ARP-1 has exhibited about 40-fold increase in the production of 
TNF-α (at 500μg/mL). As can be seen from the results presented in Figs 4.13 to 4.15, 
ARP-1 has displayed superior immunostimulatory activity than GLPs and CSPs. ARP-
1 is therefore the most immune-active polysaccharides studied in our laboratory and has 
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Fig 4.15: Immunostimulatory activities of ARP-1with respect to IL-6 production (100 ng of LPS 
that produced 492pg/mL of IL-6 was considered as positive control); control is IL-6 
produced by untreated macrophages (n = 3, p < 0.05). 
 
Overall, the results on antioxidant and immunostimulatory activities of GLPs and 
CSPs strongly indicate that they are highly potential candidates for therapeutic 
applications. Especially, high immunostimulatory activities of GLP-1, GLP-3 and 
CSP-1 are of great significance in terms of developing novel formulations for 
immunotherapy and immuno-chemotherapy (Hattori et al., 2004, Zhang et al., 2018a, 
Zhang et al., 2018b, Zhang et al., 2007). 
It is extremely pertinent at this stage to look at the literature observation that the tumours 
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cancer therapy using “immune checkpoint inhibitors” (Ji et al., 2012). This, in fact, was 
demonstrated to improve survival rates in patients with metastatic melanoma when 
treated with ipilimumab, a CTLA-1 specific antibody (Ji et al., 2012). In this context, 
immunostimulatory mushroom polysaccharides developed in this research are expected 
to play an important role in cancer therapy. These polysaccharides (GLP-1, GLP-3 and 
CSP-1) possess significantly high immune-enhancing capabilities. Pre-treatment of 
cancer patients with these novel immune-enhancing mushroom polysaccharides to 
activate tumour microenvironment followed by therapy with immune checkpoint 
inhibitors is expected to yield favourable outcomes for cancer patients. 
4.3.6.2.3 Toxicities of polysaccharides 
 
Viabilities of mouse macrophages (RAW 264.7) after treatment with polysaccharides 
were tested by MTT assay and these results are shown in Fig 4.16(a) and (b). It can be 
seen from the results presented here that, isolated mushroom polysaccharides GLPs 
and CSPs displayed low toxicities up to the concentration of 200 µg/mL indicating that 
they are non-toxic in this concentration range. These results are consistent with the 
literature reports (Jeong et al., 2004; Schepetkin & Quinn, 2006; Jeong et al., 2010; 



































Fig 4.16: Cell viability of G. lucidum & C. sinensis; (a) cell viability of GLP-1, GLP- 




Four GLP fractions and two CSP fractions were isolated the two medicinal 
mushrooms. Four of these fractions (GLP-1, GLP-2, GLP-3, CSP-1) have displayed 
significant radical scavenging activities. These activities correlated well with 
molecular masses and structural elements. GLP-1 and GLP-3 displayed highly 
significant immunostimulatory activities with respect to both cytokines and are 
extremely important candidates for immunotherapeutic applications. CSP-1 showed 
good immunostimulatory activities and ARP-1 showed extremely high 
immunostimulatory activity. Therefore, it is concluded that these polysaccharides 
(GLP-1, GLP-3 and CSP-1) possess significantly high immune-enhancing capabilities 
and are expected to activate tumour microenvironment. Pre-treatment of cancer
Concentration of polysaccharides (µg/ml) 

























0 100 200 300 400 500 600 




























patients with these novel immune-enhancing mushroom polysaccharides to activate 
tumour microenvironment followed by therapy with immune checkpoint inhibitors is 
expected to yield highly favourable outcomes for cancer patients. These activities 
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Chapter – 5 
Anticancer, prebiotics properties & 







Cancer is one of the leading causes of death in the modern world. Four most deadly 
cancers are prostate, lung, stomach, liver, and colorectal (Cui et al., 2018, Hattori et 
al., 2004). The rate of cancer-causing deaths is increasing rapidly. This chapter aims 
to make a contribution to the understanding the role of probiotic bacteria in improving 
the cancer microenvironment and to study anti-cancer and prebiotic properties of 
polysaccharides from medicinal mushrooms that can help the growth of probiotic gut 
bacteria (Singdevsachan et al., 2016, Thambiraj et al., 2015). 
Outcomes of this chapter together with excellent immunostimulatory activities 
observed in Chapter 4 are expected to make significant contribution to the field of 
cancer immunotherapy and associated regimen for the treatment of cancer. 
Chemotherapy is one of the most commonly used technique for treating cancer, 
conventional chemotherapeutic agents have great efficacy to shrink tumour cells. 
However, they are extremely toxic towards normal cells as well (Ramagopal et al., 
2017, Ramakrishnan et al., 2008, Stanculeanu et al., 2016, Vetizou et al., 2015, Zhao 
et al., 2018). Also, cancer patients generally have weak immune system. 
Immunotherapy is therefore a novel adjuvant technique to treat cancer (Syn et al., 
2017). This approach, known as immuno-chemotherapy, will not only enhance the 
immune system of the cancer patient, but also minimises serious side-effects caused 
by chemotherapy alone (Ramagopal et al., 2017, Ramakrishnan et al., 2008, 
Stanculeanu et al., 2016, Vetizou et al., 2015, Zhao et al., 2018). 
Other potential benefits of the outcomes of this chapter are grounded on building 
healthy gut microbiota. Recent literature strongly suggests that the composition of 
intestinal microbiota significantly contributes to the efficacy of immune checkpoint 
therapy (Asmar et al., 2018). Prebiotic mushroom polysaccharides are therefore of
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great interest to develop healthy gut microbiota and consequently improve the 
outcomes of immune checkpoint inhibitors to treat cancer (Gopalakrishnan et al., 
2018, Matson et al., 2018, Routy et al., 2018). Direct anticancer properties of 
mushroom polysaccharides that are aimed in this chapter are another great advantage 
in the arena of cancer treatment. Overall, the results of Chapters 4 and 5 reveal 
tremendous benefits of mushroom polysaccharides in cancer therapy, in terms of 
targeting multiple pathways to treat cancer, namely: 
 Direct anticancer effect observed in many mushroom polysaccharides 
 
 Immune enhancing potential that can be coupled with chemotherapy as well 
as immune checkpoint therapy 
 Prebiotic potentials of natural polysaccharides that can be coupled with 
immune checkpoint therapy 
 Last but not the least are antioxidant activities of mushroom polysaccharides 
that are beneficial to alleviate oxidative stress and minimise inflammation. 
Both are beneficial factors to consider while treating cancer. 
This research is therefore expected to provide multiple clues towards cancer treatment. 
 
5.2 Materials and methods 
5.2.1 Cell culturing  
PC3 cells (human prostate cancer, ATCC Cat. No. ATCC® CRL-1435TM) were 
cultured in complete RPMI 1640 media. Cells were then incubated at 37°C with 5% 
CO2 and observed until 80% confluence. Full details of this method are provided in 
chapter 3 (section 3.2.7.2.1). 
5.2.2 Anticancer activities  
To measure the cytotoxicity activities of mushroom polysaccharides, cancer cells were 
treated with these samples and incubated for 24 h. MTT assay was then performed to 
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test cytotoxicity of mushroom polysaccharides towards the targeted cancer cells. 
Detailed procedure of this method is given in chapter 3 (section 3.2.7.3). 
5.2.3 Prebiotic activities 
Polysaccharides were tested to analyse their ability to act as a carbohydrate source for 
the consumption of probiotic bacteria like Lactobacillus (L. acidophilus LAFTI L10 
and L. rhamnosus DR20) and Bifidobacteria (B. animalis BB-12 and B. lactis DR10). 
Bacteria were treated with mushroom polysaccharides and the growth was observed 
with respect to fall in pH from carbohydrate fermentation after 72 hrs. Detailed 
procedure of this method is given in chapter 3 (section 3.2.7.4). 
5.2.4 Structural characterisation of active polysaccharides    
Structure of polysaccharides is the most important feature to determines their 
functions. By Combining spectroscopic, chromatographic, and chemical techniques, 
structure of a biopolymer can be determined. Spectroscopic techniques such as Fourier 
transforms infrared spectroscopy (FT-IR) and Nuclear magnetic resonance (NMR) are 
known to be the most appropriate means to determine the detailed tertiary structures 
of polysaccharides. 
5.2.4.1 Fourier transforms infrared (FT-IR) spectroscopy 
 
Fourier transform infrared (FTIR) spectroscopic method is employed to analyse 
molecular vibrational modes and functional groups of mushroom polysaccharides. 
This method is described in chapter 3 (section 3.2.6). 
5.3 Statistical analysis 
 
All data were measured in triplicate and mean ± SD was determined. A one-way 
analysis of variance (ANOVA) and Duncan’s multiple range tests was used for data 
analysis. Statistical calculations were performed using Origin Pro 8.5 and Excel 2016. 
The data were statistically significant if p < 0.05. 
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5.4 Results and discussion 
 
               5.4.1 Anticancer activity 
 
This assay was conducted as described in section 3.2.7.3. Fig 5.1 shows the anticancer 
activities of purified fractions of polysaccharides against prostate cancer cell lines 
(PC3). Anticancer activity of CSP-1 is significantly higher than anticancer activities 
of GLP-1 and GLP-2. CSP-1 showed over 40% cytotoxicity against PC3 cell lines 
whereas GLP-1 and GLP-2 showed 31% and 35% cytotoxicity respectively. IC50 
values of these polysaccharides are given in table 5.1. A known immunostimulatory 
polysaccharide from A. rugosum (ARP) previously isolated in our laboratory (Zhang, 
2017) was also studied to assess is anticancer activity and compare with the activities 
of GLPs and CSPs (Fig 5.1(a) & 5.1(b)). ARP showed significantly higher activity as 
compare to GLP-1, GLP-2 & CSP-1 (Fig 5.1(a), 5.1(b) & 5.1(c)). It is interesting to 
note that, ARP-1 displayed significantly higher immunostimulatory activity than all 
other mushroom polysaccharides studied in this project. Also, the cytotoxic activity of 





















































Fig 5.1: % cytotoxicity of polysaccharides against PC3 cell lines; (a) % cytotoxicity of 
GLP-1 & GLP-2; (b) % cytotoxicity of CSP-1 % cytotoxicity of ARP-1 & ARP-2 
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Table 5.1: IC50 values of % cytotoxicity of polysaccharides 
 
Sr. no. Mushroom polysaccharides IC50 values 
(µM) 
1 GLP-1 1.50±0.26 
2 GLP-2 1.76±0.28 
3 CSP-1 0.998±0.05 
4 ARP-1 0.453±0.36 
5 ARP-2 0.709±02 
5.4.2 Prebiotic Activities of mushroom polysaccharides 
 
This assay was conducted as described in Chapter 3 (section 3.2.7.4). Two species 
each of Bifidobacteria (B. lactis and B. animalis) and Lactobacillus (L. acidophilus 
and L. rhamnosus) have been analysed. The results are presented in Table 5.2 below. 
Table 5.2: Prebiotic activities of polysaccharides 
Bacterial Strains Substrate pH (0 h) pH (72 h) 
 
Lactobacillus. acidophilus (LAFTI L10) 
Inulin 5.42±0.001 4.83±0 
A. rugosum 5.53±0.012 4.89±0.006 
G. lucidum 5.29±0.332 4.84±0.026 
C. sinensis 5.65±0.176 4.67±0.055 
 
Lactobacillus rhamnosus LPR 
Inulin 5.46±0 4.96±0.006 
A. rugosum 5.34±0.006 5.96±0.713 
G. lucidum 5.37±0.025 4.9±0.006 
C. sinensis 5.64±0.051 5.33±0.333 
 
Biffidobacterium animalis subsp. lactis BB-12 
Inulin 5.44±0.012 4.86±0.006 
A. rugosum 5.56±0.029 4.93±0.023 
G. lucidum 5.32±0.21 4.8±0.012 
C. sinensis 5.66±0.019 4.86±0.231 
 
Biffidobacterium animalis DR 10 (BF - 420) 
Inulin 5.47±0.026 5.36±0.015 
A. rugosum 5.59±0.035 5.86±0.699 
G. lucidum 5.37±0.034 5.26±0.017 
C. sinensis 5.71±0.041 5.42±0.172 
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Some of the bacterial species showed significant decrease of pH (Table 5.2) as a 
function of incubation time when treated with some mushroom polysaccharides in 
anaerobic conditions which indicates the fermentation of the polysaccharide 
compounds. 
Results presented in Table 5.2 indicate that: 
 
 the polysaccharides form all the three mushrooms (GLPs, CSPs and ARPs) 
displayed prebiotic activities against two bacterial species, namely, 
Lactobacillus acidophilus and Bifidobacteria BB-12 
 Only two mushroom polysaccharides (GLPs and CSPs) showed prebiotic 
activities against Lactobacillus rhamnosus, but ARPs did not display any 
activity against this species. 
 No observable prebiotic activities were observed for any of the mushroom 
polysaccharides against Biffidobacterium animalis DR 10 (BF - 420). The test 
against this species is inconclusive as the known prebiotic inulin also did not 
show observable activity. 
These results indicate that three of the tested probiotic bacteria grow well by utilising 
polysaccharides from G. lucidum and C. sinensis as carbohydrate sources but only two 
of the species grew with A. rugosum (Table 5.2). Inulin, a well-known prebiotic 
polysaccharide, was used in this study as a standard and the results were compared 
with those from mushroom polysaccharides (Table 5.2). Overall CSP showed better 
prebiotic activity than GLP for L. acidophilus, B. lactis and B. animalis bacterial 
species tested in this research. Whereas GLP showed higher activity for L. rhamnosus 
than CSP. CSP has also outperformed inulin with respect to both the strains of 
Bifidobacteria (table 5.2). GLP and CSP both have showed superior activity with 
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respect to Lactobacillus strains than Bifidobacteria strains. These preliminary results 
on prebiotic assessment of mushroom polysaccharides indicate that mushroom 
polysaccharides, GLPs and CSPs, are possible candidates for their use as prebiotic 
agents. Previous research on polysaccharides (Thambiraj et al., 2015, Zhang et al., 
2013, Zhang et al., 2012) in combination with the results presented in this chapter 
demonstrate that GLP and CSP are strong candidates to be used as antioxidant, 
immunostimulatory, prebiotic and cancer preventing agents. Therefore, it can be 
concluded that these polysaccharides have immense potential as immunotherapeutic 
and immune-chemotherapeutic agents. 
Overall, the results given in this thesis suggests the immune enhancing, prebiotic and 
direct anticancer activities of polysaccharides from G. lucidum and C. sinensis (GLPs 
and CSPs). It is therefore concluded that these polysaccharides form potential 
candidates for combination “immuno-chemotherapy”. Also, Treatment of cancer 
patients with prebiotic mushroom polysaccharides identified in this research to 
improve gut microbiota, followed by therapy with suitable immune checkpoint 
inhibitors is expected to produce enhanced outcome for cancer patients 
(Gopalakrishnan et al., 2018, Matson et al., 2018, Routy et al., 2018). It is in this 
context that the immune enhancing and prebiotic mushroom polysaccharides 
discovered in this research assume a special status to treat cancer. Development of 
suitable immunomodulatory and prebiotic formulations is the direction of future 
research in our laboratory. Such formulations are expected to be extremely beneficial 
to treat cancer. 
5.4.3 FT-IR spectroscopic characterisation of mushroom polysaccharides 
 
Fig 5.2 presents FT-IR spectra of G. lucidum polysaccharides (GLP-1, GLP-2, GLP- 
3 and GLP-4). 
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GLP-1 – showed peaks corresponding to β-glycosidic linkage (895 cm-1) (Fig. 5.2 (a)) 
(Zhang et al., 2014, Yang and Zhang, 2009, Thambiraj et al., 2015, Pawar and Lalitha, 
2014). The spectrum also showed two strong absorption bands at 1069 cm-1 and 1034 
cm-1 (corresponding to C-O stretching vibrations related to glycosidic linkage) 
indicating the presence of furanose sugar in GLP-1 (Mohamed et al., 2017, Thambiraj 
et al., 2015, Zhang et al., 2014). The rest of the vibrational bands conform to a 
polysaccharide structure. A broad band on 3332 cm-1 indicates the hydroxyl stretching 
vibrations of the polysaccharide. There is another peak at 2890 cm-1 which belongs to 
C-H stretching vibrations (Mohamed et al., 2017, Zhang et al., 2014). These 
observations lead to the conclusion that GLP-1 contains furanose sugars with β- 
glycosidic linkages. 
GLP-2 – (Fig. 5.2 (b)) has peaks at 898 cm-1 represents the presence of β-glycosidic 
linkage (Mohamed et al., 2017, Thambiraj et al., 2015, Zhang et al., 2014). The two 
strong absorption peaks in the range of 1069 cm-1 & 1037 cm-1 (corresponding to C- O 
stretching vibrations related to glycosidic linkage) indicating the presence of furanose 
sugars in GLP-2 (Mohamed et al., 2017, Zhang et al., 2014). Rest of the FT- IR bands 
confirm to a polysaccharide structure. These observations confirm that GLP- 2 also 
contains furanose sugars with β-glycosidic linkages. 
GLP-3 – has peaks at 865 cm-1 (Fig 5.2 (c)) indicating the presence of β-glycosidic 
linkage (Mohamed et al., 2017, Thambiraj et al., 2015, Zhang et al., 2014). The three 
strong absorption peaks in the range of 1067 cm-1, 1035 cm-1 & 983 cm-1 
(corresponding to C-O stretching vibrations related to glycosidic linkage) indicating 
the presence of pyranose sugars in GLP-3 (Mohamed et al., 2017, Zhang et al., 2014). 
The rest of the FT-IR bands confirm to a polysaccharide structure. These observations 
confirm that GLP-3 also have β-glycosidic linkages with pyranose ring structure. 
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GLP-4 – has peaks at 833 cm-1 and 766 cm-1 (Fig 5.2 (d)) indicating the presence of 
both α- and β-glycosidic linkages (Mohamed et al., 2017, Thambiraj et al., 2015, 
Zhang et al., 2014). The three strong absorption peaks in the range of 1066cm-1, 1032 
cm-1 and 996 cm-1 (corresponding to C-O stretching vibrations related to glycosidic 
linkage) indicating the presence of pyranose sugars in GLP-3 (Mohamed et al., 2017, 
Zhang et al., 2014). The rest of the FT-IR bands confirm to a polysaccharide structure. 
These observations confirm that GLP-4 contains pyranose sugars with α- and β- 
glycosidic linkages. 
CSP-1 - has peaks in region 891 cm-1 and 760 cm-1 (Fig 5.3 (a)) representing the 
presence of α-, β-glycosidic linkages (Mohamed et al., 2017, Thambiraj et al., 2015, 
Zhang et al., 2014). The three strong absorption peaks in the range of 1072 cm-1, 1016 
cm-1 and 975 cm-1 (corresponding to C-O stretching vibrations related to glycosidic 
linkage) indicating the presence of pyranose sugars in CSP-1 (Mohamed et al., 2017, 
Zhang et al., 2014). The rest of the FT-IR bands confirm to a polysaccharide structure. 
A broad band on 3332 cm-1 indicates the hydroxyl stretching vibrations of the 
polysaccharide. There is another peack at 2890 cm-1 which belongs to C-H stretching 
vibrations. These observations confirm that CSP-1 contains pyranose sugars with α- 
& β-glycosidic linkages. 
CSP-2 - has peaks in region 833 cm-1 and 759 cm-1 (Fig 5.3 (b)) representing the 
presence of α- and β-glycosidic linkage (Mohamed et al., 2017, Thambiraj et al., 2015, 
Zhang et al., 2014). The three strong absorption peaks in the range of 1077 cm-1, 1014 
cm-1 & 999 cm-1 (corresponding to C-O stretching vibrations related to glycosidic 
linkage) indicating the presence of pyranose sugars in CSP-2 (Mohamed et al., 2017, 
Zhang et al., 2014). The rest of the FT-IR bands confirm to a polysaccharide structure. 
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Fig 5.3: FTIR spectra of CSP-1 & CSP-2 
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5.5 Conclusion 
ARP-1 with highly significant immune enhancing property has also displayed good 
anticancer property. This is a significant finding amongst the three mushroom 
polysaccharides studied, that ARPs have outperformed in terms of both 
immunostimulatory and anticancer properties when compared with the other two 
mushroom polysaccharides. CSPs have displayed relatively higher anticancer and higher 
prebiotic properties when compared to GLPs. Even though ARPs have displayed higher 
anticancer activities, their prebiotic activities are relatively lower. In terms of prebiotic 
activities GLPs and CSPs have displayed comparable activities that were highly 
significant. However, ARPs showed lower prebiotic activities. 
Overall, the results presented in this this chapter strongly suggest the prebiotic and direct 
anticancer activities of polysaccharides from G. lucidum and C. sinensis (GLPs and 
CSPs). It is therefore concluded that these polysaccharides form potential candidates for 
combination “immuno-chemotherapy”. It is concluded that, treatment of cancer patients 
with prebiotic mushroom polysaccharides identified in this research to improve gut 
microbiota, followed by therapy with suitable immune checkpoint inhibitors is expected 
to produce enhanced outcomes for cancer patients. It is in this context that the prebiotic 
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6.1 Overall conclusions and suggestions for further research in this research area 
Sophisticated techniques now exist to carry out systematic scientific investigations to 
determine biological activities and to evaluate structure-activity correlation of 
bioactive polysaccharides. Combining such scientific understanding with a valuable 
traditional knowledge is expected to provide way forward towards the discovery of 
novel and effective therapeutics to treat cancer and other life-threatening diseases. The 
main objectives of this thesis were to discover potent immune enhancing, prebiotic and 
anticancer polysaccharides, with least toxicity. In order to achieve these goals, 
polysaccharides were extracted from medicinal mushrooms, purified and a spectrum 
of biological activities were evaluated. Chemical compositions and FT-IR structural 
characterisation of the active polysaccharides were evaluated. Several mushroom 
polysaccharides isolated in this research exhibited significant antioxidant, 
immunomodulatory, prebiotic and anti-cancer properties. In addition to the 
polysaccharides from the two selected mushrooms (G. lucidum and C. sinensis), 
polysaccharides from another traditionally well-known mushroom (A. rugusum) have 
also been considered for this research (these samples were available in our research 
laboratory from a previous research project). ARPs have proven to outperform in terms 
of immunomodulatory and anticancer properties amongst all. Whereas GLPs and CSPs 
displayed extremely significant antioxidant, immunomodulatory, prebiotic properties 
and their anticancer activities were average. Noteworthy observation is that the GLPs 
and CSPs displayed better prebiotic activities than even ARPs. All these results are 
presented in Chapters 4 and 5 
Chapter 5 also presents the results of FT-IR structural characterisation. Vibrational 
bands detected in FT-IR spectra have provided important structural elements of the 
polysaccharides and provided information on α- and β-glycosidic linkages of these 
polysaccharides. 
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Findings of this research suggest that the polysaccharides from G.lucidum and 
C.sinensis demonstrate the potential of GLPs and CSPs to be used in 
immunomodulatory and prebiotic formulations (GLPs being more active). It was also 
an important finding that ARPs displayed highly significant anticancer activities along 
with high immunomodulatory properties. A. rugosum polysaccharides are indeed 
extremely important candidates for anticancer applications. 
A few important directions for further research are: 
 Development of immunomodulatory formulations based on the active 
polysaccharides identified in this research. It is highly likely that such 
formulations would enhance bioactivities by activating multiple immune 
pathways. 
 Determination of full secondary structures of active polysaccharides 
employing NMR and other spectroscopic methods. 
 A detailed investigation of anticancer activities with different cancer cell lines 
and studies on animal models will be beneficial. 
Overall, the research carried out as part of this Master of Research led to the discovery 
of 3 important polysaccharides with significant antioxidant, immunostimulatory and 
prebiotic properties. 
 
